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ABSTRACT
Introduction Daily radiotherapy delivered with 
radiosensitisation offers patients with muscle invasive 
bladder cancer (MIBC) comparable outcomes to 
cystectomy with functional organ preservation. Most 
recurrences following radiotherapy occur within the 
bladder. Increasing the delivered radiotherapy dose to the 
tumour may further improve local control. Developments in 
image- guided radiotherapy have allowed bladder tumour- 
focused ‘plan of the day’ radiotherapy delivery. We aim to 
test within a randomised multicentre phase II trial whether 
this technique will enable dose escalation with acceptable 
rates of toxicity.
Methods and analysis Patients with T2- T4aN0M0 
unifocal MIBC will be randomised (1:1:2) between 
standard/control whole bladder single plan radiotherapy, 
standard dose adaptive tumour- focused radiotherapy or 
dose- escalated adaptive tumour- focused radiotherapy 
(DART). Adaptive tumour- focused radiotherapy will use 
a library of three plans (small, medium and large) for 
treatment. A cone beam CT taken prior to each treatment 
will be used to visualise the anatomy and inform selection 
of the most appropriate plan for treatment.
Two radiotherapy fractionation schedules (32f and 20f) 
are permitted. A minimum of 120 participants will be 
randomised in each fractionation cohort (to ensure 57 
evaluable DART patients per cohort).
A comprehensive radiotherapy quality assurance 
programme including pretrial and on- trial components 
is instituted to ensure standardisation of radiotherapy 
planning and delivery.
The trial has a two- stage non- comparative design. The 
primary end point of stage I is the proportion of patients 
meeting predefined normal tissue constraints in the DART 
group. The primary end point of stage II is late Common 
Terminology Criteria for Adverse Events grade 3 or worse 
toxicity aiming to exclude a rate of >20% (80% power and 
5% alpha, one sided) in each DART fractionation cohort. 
Secondary end points include locoregional MIBC control, 
progression- free survival overall survival and patient- 
reported outcomes.
Ethics and dissemination This clinical trial is 
approved by the London- Surrey Borders Research Ethics 
Committee (15/LO/0539). The results when available will 
be disseminated via peer- reviewed scientific journals, 
conference presentations and submission to regulatory 
authorities.
Trial registration number NCT02447549; Pre-results
ARTICLE SUMMARY
We present the first international randomised 
controlled trial protocol evaluating a dose- 
escalated tumour- focused image- guided 
adaptive radiotherapy technique. The study 
Strengths and limitations of this study
 ► Phase II international multicentre randomised con-
trolled study evaluating a novel adaptive radiothera-
py technique (strength).
 ► Treatment allocation favours 75% of participants 
receiving novel adaptive radiotherapy techniques 
(strength).
 ► Detailed guidance and training are provided for the 
contouring, planning and delivery of this radiother-
apy technique to ensure standardisation across 
participating centres with robust pretrial and on- 
trial radiotherapy quality assurance programme 
(strength).
 ► Primary end point focus is based on determining 
safety of treatment based on late grade 3 toxicity 
scoring (strength).
 ► Non- comparative trial design (limitation).
 on F









pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm
















pen: first published as 10.1136/bm






2 Hafeez S, et al. BMJ Open 2020;10:e041005. doi:10.1136/bmjopen-2020-041005
Open access 
population are patients with unifocal localised muscle 
invasive bladder cancer. Patients will be randomised 
(1:1:2) between standard (control) whole bladder single 
plan radiotherapy (WBRT), or standard dose adaptive 
tumour- focused radiotherapy (SART) or dose- escalated 
adaptive tumour- focused radiotherapy (DART). For those 
randomised to adaptive tumour- focused radiotherapy 
groups treatment will be delivered using a library of three 
plans (plan of the day). If successful, the trial will demon-
strate feasibly of multicentre implementation of this new 
radiotherapy technique and inform design of a future 
phase III trial to establish the optimum organ preserving 
treatment option for patients with MIBC.
INTRODUCTION
Radical management of localised muscle invasive bladder 
cancer (MIBC) involves either radical cystectomy or a 
course of daily radiotherapy delivered with radiosensi-
tisation over 4–7 weeks.1–5 Although both have compa-
rable overall survival outcomes in appropriately selected 
patients, radiotherapy offers opportunity for cancer cure 
with functional organ preservation.6
Most recurrences following radiotherapy occur within 
the bladder, the majority of which are believed to occur 
at the original MIBC tumour site, suggesting persistent 
occult local disease.7 The modelled dose- response rela-
tionship of MIBC to radiotherapy suggests improved local 
control and overall survival would be expected at higher 
doses.8–10
The ability to safely increase dose beyond the current 
accepted standard has been restrained by reliable radio-
therapy delivery to the bladder. The bladder is a mobile 
organ which is subject to marked shape and volume 
change during the course of treatment.11–13 This bladder 
motion means historically up to 57% of fractions (f) incur 
some element of geographical miss even when safety 
margins of up to 1.5 cm are applied to create the plan-
ning target volume (PTV).14 The expected consequence 
of improving bladder radiotherapy targeting would be 
improved tumour control and reduced treatment- related 
toxicity.
Optimisation of target coverage has been enabled 
by technology integrated on current generation linear 
accelerators which allow a three- dimensional (3D) image 
known as a cone beam CT (CBCT) to be acquired. This 
is of sufficient contrast to allow soft tissue visualisation. 
When acquired immediately prior to treatment, it informs 
positional adjustment to ensure coverage of target with 
the radiotherapy plan.15
A solution enabled by CBCT soft tissue visualisation 
is ‘plan of the day’. Rather than having a single plan 
available for treatment, a library of plans of varying 
PTV bladder sizes can be created to cover the range of 
expected filling and positional variation of the bladder. A 
plan which best fits the bladder target with least normal 
tissue irradiation as seen on CBCT immediately prior to 
treatment is then selected for use each day.14 In bladder 
cancer radiotherapy treatment delivery based on a 
library of plans has reported benefit in reducing normal 
tissue irradiation compared with single plan treatment 
delivery.16–19 It is yet to be demonstrated whether this 
approach translates to improved clinical outcomes.
Tumour- focused radiotherapy delivery may offer 
further opportunity to reduce normal tissue irradia-
tion. Sparing the uninvolved bladder does not appear 
to compromise local control but randomised controlled 
studies have failed to demonstrate statistically significant 
improvement in toxicity.20 21 Bladder sparing is unlikely 
to have been optimally achieved in radiotherapy delivery 
predating CBCT image guidance given the positional 
uncertainties, the large margins applied and treatment 
delivery on an empty bladder.
In a single- centre phase I study (NCT01124682), feasi-
bility and safety of tumour- focused dose escalation to 
70 Gy delivered using plan of the day has been demon-
strated. The RAIDER trial seeks to examine feasibility 
of this approach in a multicentre setting and to deter-
mine the clinical benefit of bladder tumour- focused dose 
escalation.
Below, we describe the RAIDER trial protocol with 
particular emphasis on the radiotherapy procedural 
aspects, including preparatory imaging, treatment plan-
ning and delivery with the aim of providing comprehen-
sive description of the radiotherapy implemented for the 
study.
Hypothesis
Tumour- focused dose- escalated adaptive radiotherapy 
using library of three plans can be translated to multiple 
centres. It will be well tolerated and offer the opportunity 




RAIDER is an international multicentre, multi- arm, two- 
stage non- blinded phase II randomised controlled trial 
conducted in accordance with the Research Governance 
Framework for Health and Social Care and principles of 
Good Clinical Practice. The trial is registered on the  clin-
icaltrials. gov database (NCT02447549) and is included in 
the National Institute for Health Research (NIHR) Clin-
ical Research Network portfolio. The final ethics approved 
version of the RAIDER trial protocol is provided in the 
supplementary files (online supplemental appendix 1).
Patients will be randomised (1:1:2) between standard 
(control) WBRT, SART or DART. Treatment allocation 
is by minimisation with a random element; balancing 
factors will be centre, neoadjuvant chemotherapy useand 
concomitant radiosensitising therapy use. Randomisation 
will take place centrally by the Clinical Trials and Statis-
tics Unit, The Institute of Cancer Research (ICR- CTSU) 
within a maximum of 10 weeks prior to the planned 
radiotherapy start date.
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Within the UK, there are two commonly used radio-
therapy schedules to treat bladder cancer, both supported 
by the National Institute for Health and Clinical Excel-
lence.1 Therefore, to accommodate this practice radio-
therapy will be delivered daily in either 20f over 4 weeks 
or 32f over 6.5 weeks in accordance with the participating 
centre’s standard practice. The choice of fractionation 
will be confirmed by each site before trial commence-
ment and will be used for all patients at that site. The two 
fractionation cohorts will be analysed separately for the 
primary end point.
For stage I, the primary end point is the proportion of 
participants in the DART group meeting the predefined 
normal tissue radiotherapy dose constraints. The 
secondary end points of stage I are recruitment rate and 
the ability of the participating centres to deliver SART 
and DART treatment as per protocol.
For stage II, the primary end point is grade 3 or greater 
toxicity occurring 6–18 months following radiotherapy 
as assessed using Common Terminology Criteria for 
Adverse Events (CTCAE V.4). The secondary end points 
of stage II are acute toxicity as measured by CTCAE V.4, 
patient- reported outcomes as measured by a number of 
instruments including the Patient- Reported Outcomes 
version of the Common Terminology Criteria for Adverse 
Events (PRO- CTCAE), Assessment of Late Effects of 
RadioTherapy- Bowel, the King’s Health Question-
naire, sexual function questions and the 5- level EQ- 5D 
version. Additional secondary end points include health 
economic- related measures, locoregional MIBC control, 
progression- free survival and overall survival.
The trial has a number of exploratory secondary end 
points related to use of adaptive plans including appro-
priate identification of plan selection, target coverage 
and dose volume comparison between control (WBRT) 
and adaptive (SART and DART) planning.
Figure 1 shows the trial schema and overview of 
follow- up. Table 1 provides summary of the scheduled 
prerandomisation, on treatment and post- treatment 
assessments.
Participants and eligibility
Total target recruitment is set at a minimum of 240 partic-
ipants with a minimum 120 be recruited to each fraction-
ation cohort (20f or 32f cohort). The final sample size 
in each fractionation cohort will be determined as that 
sufficient to accrue 57 DART patients evaluable for the 
primary end point of late toxicity.
Patients with histological or cytological confirmation 
of unifocal (T2- T4aN0M0) transitional cell carcinoma 
of the bladder suitable for radical daily radiotherapy will 
be approached for inclusion. Eligible patients should be 
willing to accept assessment with cystoscopy and follow- up 
schedule as outlined in table 1.
Patients with multifocal invasive disease or history of 
other malignancy within 2 years of randomisation except 
for non- melanomatous skin carcinoma, previous non- 
muscle invasive bladder tumours and low risk prostate 
cancer (as defined by National Comprehensive Cancer 
Network, NCCN risk stratification as T1/T2a, Gleason 6 
Prostate Specific Antigen (PSA) <10) will be excluded. 
Those with bilateral prosthetic hip replacements, previous 
history of radiation to the pelvis or other contraindication 
to pelvic radiotherapy, for example, inflammatory bowel 
disease will also be excluded.
Study treatment
All participants should have had a transurethral resec-
tion of the bladder tumour (TURBT) with completion 
of a bladder map by the performing urologist to aid 
tumour localisation for radiotherapy. Insertion of fiducial 
markers to further assist tumour localisation for radio-
therapy is also recommended at the time of cystoscopy. 
Neoadjuvant chemotherapy use prior to randomisation is 
permitted and encouraged for suitable patients.
Radiotherapy should be planned to commence within 
a maximum of 10 weeks after randomisation or neoadju-
vant chemotherapy completion (if used), to allow suffi-
cient time for treatment planning.
Delivery of radiotherapy with concomitant radiosen-
tiser is permitted. Regimes approved for use within the 
protocol include mitomycin C and 5- fluorouracil,2 gemcit-
abine,22 cisplatin23 or carbogen.3 Each centre should aim 
to use the same regimen for all their participants. Where 
this is not possible appropriate substitution is permitted 
for that participant following discussion with the RAIDER 
lead investigators.
Participants allocated to the WBRT (control) group will 
have one radiotherapy plan created treating the whole 
empty bladder to either 64 Gy in 32f or 55 Gy in 20f. A 
CBCT scan acquired just prior to treatment delivery can 
be used by the local investigators to inform an online 
position correction in accordance with National Radio-
therapy Implementation Group Report on Image- Guided 
Radiotherapy (IGRT)15 and standard local practice.
Participants allocated to the adaptive tumour- focused 
planning groups (SART and DART) will have three radio-
therapy plans generated a small, medium and large plan. 
The bladder tumour boost volume will be treated to either 
standard dose (64 Gy in 32f or 55 Gy in 20f) or escalated 
dose (70 Gy in 32f or 60 Gy in 20f) depending on whether 
the participant is allocated to SART or DART, respectively. 
The uninvolved bladder will receive a lower planned dose 
either 52 Gy in 32f or 46 Gy in 20f depending on fraction-
ation cohort irrespective of SART or DART randomisa-
tion. A CBCT taken immediately prior to each treatment 
delivery will be used to select the most appropriate ‘plan 
of the day’ depending on the bladder volume and shape. 
A second trained individual verifies the plan selected for 
treatment.
Plan selection is authorised to be carried out only by 
radiographers or other delegated practitioners who have 
attained concordance with the gold standard PTV selec-
tion through the Radiotherapy Trials Quality Assurance 
Group (RTTQA) IGRT credentialing for UK centres and 
Trans Tasman Radiation Oncology Group (TROG) IGRT 
 on F
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credentialing for Australian and New Zealand centres. 
This is to ensure all those participating in plan selection 
have the necessary advanced skill level required for the 
study.
A comprehensive quality assurance (QA) programme 
has been implemented for the RAIDER trial. This includes 
pretrial and on- trial components. Selection of appropriate 
treatment plans for the adaptive planning group will also 
be independently monitored during patient recruitment 
as part of the radiotherapy QA process.
Radiotherapy planning and delivery
Radiotherapy planning CT scan
Bladder preparation procedures vary depending on 
randomisation group. For WBRT, an empty bladder 
is required. Patients should be asked to abstain from 
drinking fluids for 30 min before the scheduled planning 
CT scan and are required to void their bladder immedi-
ately before the planning CT scan is acquired (CT0).
For both SART and DART groups patients are instructed 
to void their bladder and then drink 350 mL of water. Two 
Figure 1 Trial schema. f, fraction; PRO, patient- reported outcome; RTOG, Radiation Therapy Oncology Group.
 on F
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planning scans are acquired, the first at 30 min following 
drinking (CT30) and the second 60 min following 
drinking (CT60). No voiding is permitted between the 
two scans. However, if voiding is unavoidable because of 
patient discomfort, then only the available CT30 scan is 
used for planning.
Given bladder deformation can occur with a loaded 
rectum, all participants should be encouraged to evac-
uate their bowels of flatus and faeces prior to acquisition 
of the radiotherapy planning scanning. The use of micro-
enemas is permitted if it is standard local practice but is 
not mandated.
All patients will be positioned supine with arms comfort-
ably positioned out of the radiotherapy field using appro-
priate immobilisation techniques for planning CT scan 
acquisition. CT slices of ≤3 mm thickness will be obtained 
from at least 4 cm above the dome of the bladder to 2 
cm below the ischial tuberosities. No oral or intravenous 
contrast is required.
The planning CT scan is exported via DICOM transfer 
to the radiotherapy treatment planning system for target 
and organs at risk (OAR) localisation. Bladder filling 
occurring between CT30 and CT60 scans is determined 
for those randomised to SART or DART. This is achieved 
by fusing both CT30 and CT60 data sets and contouring 
the bladder on both scans. If the difference in bladder 
volume between the two scans is <50 mL, that is, no signif-
icant bladder filling occurs, then all target and OAR 
contours are created using CT30. If difference in bladder 
filling is >50 mL, that is, bladder filling occurs, the target 
volumes for large plan is created using CT60 anatomy.
Target volume definition
Volumes will be defined according to the International 
Commission on Radiation Units and Measurements 
(ICRU) report 50, supplement report ICRU 62, and 
ICRU 83.24 Consistent structure naming convention 
for target volumes and organs at risk is adopted for all 
patients participating within the trial.
The gross tumour volume (GTV) is defined as the 
bladder tumour or the resected tumour bed. It is delin-
eated using position of fiducial markers (where available), 
diagnostic imaging (prior to neoadjuvant chemotherapy 
where applicable) and the surgical bladder map (where 
available). When delineating the tumour any extravesical 
tumour should be included in the GTV. If no tumour is 
visible then the appropriate section of the bladder should 
be included based on surgical bladder map following 
discussion with the urologist who performed the TURBT. 
Alternatively, repeating the cystoscopy and placing fidu-
cial markers adjacent to resected bladder tumour scar 
should be considered.
The clinical target volume (CTV) is contoured to 
encompass the GTV, the whole bladder and any area of 
extravesical spread. The CTV should also include 1.5 cm 
of prostatic urethra in male patients or 1 cm of urethra 
in female patients if tumour is at the base of bladder or if 
distant carcinoma in situ is present.
A checklist for contouring is provided in the radio-
therapy planning and delivery guidelines (online supple-
mental appendix 2, p. 17). The expansions applied to 
generate the PTVs are summarised in table 2. The PTV 
expansion margins were derived from earlier phase I 
work.14 16 25
Organs at risk delineation
Organs at risk (OARs) are identified as other bowel, 
rectum and femoral heads in all groups. To quantify 
normal bladder sparing, the normal bladder outside the 
boost (PTV2) is also identified for participants in the 
adaptive tumour- focused radiotherapy groups.
All OARs will be outlined as solid structures by defining 
their outer wall. The rectum is outlined to include the full 
circumference and rectal contents. The rectal outlining 
should extend from the lowest level of the ischial tuber-
osities to the rectosigmoid junction which identified as 
the level at which there is an anterior inflection of the 
bowel, best appreciated on sagittal reconstructions on the 
CT planning scan.
The small and large bowel (including sigmoid colon) 
will be outlined as a single structure labelled ‘other bowel’. 
Small and large bowel visible on relevant axial slices of 
the planning scan will be outlined as individual loops. 
The cranial extent of ‘other bowel’ outlining should be 
2 cm beyond the superior extent of the standard PTV or 
large PTV as appropriate.
Both the femoral heads are outlined to the bottom 
of the femoral head curvature. The femoral necks not 
included.
The normal bladder outside the boost (PTV2) is created 
by subtracting the PTV2 from the corresponding CTV.
Radiotherapy planning
All patients are CT planned. For WBRT, a single plan 
created using either 3D conformal radiotherapy (3DCRT) 
with three or four fields, static 5-–7- field intensity modu-
lated radiotherapy (IMRT) or volumetric modulated 
arc radiotherapy (VMAT) technique is permitted. It is 
accepted that the preferred treatment planning method 
will vary between participating sites but should be spec-
ified in the centre’s pretrial process document and be 
used for all patients enrolled at that centre. Changes in 
centres preferred planning method from that specified 
should be brought to the attention of RTTQA.
For participants in the adaptive tumour- focused radio-
therapy groups, the planning and dose calculation is done 
on CT30 data set, therefore all target and OARs volumes 
are assigned to the CT30 scan. They will have three plans 
created (small, medium or large) generated from the 
respective PTV and PTV2 volumes. To enable bladder 
sparing, these plans are created using either static 5–7- 
field IMRT or VMAT. The same technique should be used 
for all patients randomised to adaptive tumour- focused 
radiotherapy at that centre.
The prescription doses for the PTV are outlined in 
table 3. All plans should be created with the intention 
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of achieving the target volume objectives as outlined in 
table 4. Dose to OARs should be as low possible. The 
OARs dose volume constraints for both fractionations are 
summarised in table 5.
The other bowel, rectumand femoral heads constraints 
for the 32f schedule were derived from previous phase 
III prostate (CHHiP, convential or hypofractionated 
high dose intensity modulated radiotherapy for pros-
tate cancer; ISRCTN97182923) and bladder (BC2001; 
ISRCTN68324339) studies2 26 27 and from phase I work.28 
The absence of previously defined OARs constraints when 
dose escalating in 20f meant that the OARs constraints 
at higher doses were marginally more conservative than 
if otherwise converted exactly from 32f constraint level 
using the linear quadratic model alone.29 The constraints 
used for the 20f schedule were estimated from the 32f 
constraint level using the linear quadratic equation 
assuming that all α/β of organs at risk is 3 but the dose 
constraint is reached in 3 Gy per fraction.
Dose objectives to the PTV should not be compromised 
to achieve dose to OAR constraints. The recommended 
hierarchy of planning priorities is providing radiotherapy 
planning and delivery guidelines (online supplemental 
appendix 2, p. 27).
For patients randomised to WBRT, it is at the local 
principal investigator’s (PI) discretion to accept the 
OAR doses. For those randomised to adaptive tumour- 
focused radiotherapy groups it is recommended that the 
predefined optimal dose constraints are met for the small 
plan, and the mandatory constraints for the medium 
plan wherever possible. It is accepted that the rectum 
and bowel dose constraints of the large plan may not be 
met despite adequate optimisation. Assessment of ‘other 
bowel’ dose on the large plan represents an overestima-
tion of actual dose compared with ‘other bowel’ when this 
plan is actually used to deliver treatment. This is because 
when the large plan is selected for treatment, a propor-
tion of bowel moves out of the field with bladder filling.
For patients allocated to DART, if the mandatory 
constraints are not met on the medium plan advice must 
be sought from the RTTQA team. Decision will be then 
made by the RAIDER trial team regarding the appropri-
ateness of proceeding at the DART prescription dose or 
to lowering the prescribed dose as per SART randomi-
sation. It is therefore recommended that the medium 
plan be optimised first. If patients are not able to receive 
DART (in either fractionation cohort) for any reason 
then details of the deviation from allocated treatment will 
be requested
Preradiotherapy checks
To minimise risk of error at the time of plan importing, 
exporting and plan selection, it is recommended that 
each plan, beam name and ID reflect the assigned plan, 
for example, Sm_Plan used for labelling the beams 
making up the small plan in the adaptive tumour- 
focused radiotherapy groups. It is also important to 
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3DCRT and IMRT cannot mix beams from different 
plans at the time of exporting or deliver more than one 
plan at treatment.
Treatment scheduling
Radiotherapy can start on any day of the week and should 
be delivered 5 days a week until completion. Interrup-
tions during radiotherapy should be avoided as they have 
detrimental effect on outcome.30 All missed fractions are 
to be reported to the ICR- CTSU and RTTQA team.
In the event of missed fractions due to machine 
breakdown, bank holiday or any other logistical reason 
compensation for the missed fraction is advised. This is 
expected to be achieved by either treating at a weekend 
or by hyperfractionating, that is, undertaking two frac-
tions a day (ideally on a Friday) with a minimum 6- hour 
gap between treatments. Should a treatment break 
occur due to toxicity, centres are advised to contact ICR- 
CTSU and/or RTTQA. Compensation is not expected 
in circumstances where missed treatment is a result of 
radiotherapy- related toxicity.
For those allocated to adaptive tumour- focused radio-
therapy groups if plan selection capabilities are unavail-
able, either because of absence of trained staff, machine 
breakdown and/or gap day treatment, patients may be 
treated for up to 5 days using the PTV medium plan 
without plan selection. These pretreatment CBCTs (if 
acquired) should be sent to RTTQA for review.
Treatment delivery
The same patient preparation instructions used at plan-
ning CT should be implemented prior to each fraction 
delivered.
For those patients allocated to SART or DART, CBCT of 
the pelvis should be acquired prior to each fraction. For 
those patients randomised to WBRT, pretreatment CBCT 
should be used in accordance with guidance provided 
in the NRIG IGRT report.15 It is therefore expected that 
this CBCT will inform appropriate corrections (either 
manual or automatic) to be applied prior to the delivered 
fraction in accordance with the centre’s local practice to 
ensure that treatment is accurately directed. Any changes 
made on the basis of the scan including exposures that do 
not lead to treatment because of patient factors should be 
reported in the case report forms (CRF) and to RTTQA.
For those randomised to adaptive tumour- focused 
radiotherapy groups, the pretreatment CBCT is acquired 
and registered to bone according to the guidance 
provided in the NRIG IGRT report.15 An appropriately 
trained radiographer or practitioner reviews the bone- 
matched CBCT assessing the bladder size and position in 
relation to the PTVs and the coverage they provide.
To assist trained radiographers or practitioners with 
optimal plan selection the following sequential assess-
ment is advised:
i. Following CBCT acquisition, the bladder filling and 
shape is first checked against CTV_30 contour. If the 
Table 3 Prescription doses
Patient randomisation Volume
32 fraction cohort 20 fraction cohort
Dose (Gy) Dose per fraction (Gy) Dose (Gy) Dose per fraction (Gy)
Group 1
WBRT
PTV_Std 64 2 55 2.75
Group 2
SART
PTV2 64 2 55 2.75
52 1.625 46 2.3
Group 3
DART
PTV2 70 2.1875 60 3
52 1.625 46 2.3
DART, dose- escalated adaptive tumour- focused radiotherapy; PTV, planning target volume; SART, standard dose adaptive tumour- focused 
radiotherapy; WBRT, whole bladder single plan radiotherapy.
Table 4 Target volume dose objectives
Volume Dose constraints Optimal Mandatory
PTV2 D98% ≥95% of prescribed dose ≥90% of prescribed dose
D50%* – ±1% of prescribed dose
D2% ≤105% of prescribed dose ≤107% of prescribed dose
PTV
(PTV–PTV2)
D98% ≥95% of prescribed dose ≥90% of prescribed dose
*Please note that D50% constraint refers only to PTV2. PTV D50% is likely to be exceeded depending on size of PTV2. Therefore, no compromise 
to PTV2 coverage should be made at the expense of achieving D50% PTV constraint.
PTV, planning target volume.
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bladder is of similar size and shape to the CTV at 
planning (ie, CTV_30), then the small plan should 
be considered in the first instance for treatment.
ii. The appropriate plan provides suitable coverage 
of the CTV and boost region by the corresponding 
PTV and PTV2 contours with minimal normal tissue 
irradiation.
iii. Manual (soft tissue) moves should be made to ensure 
the bladder (CTV) is adequately covered while select-
ing the smallest plan possible to spare normal tissue.
iv. Care should be taken when applying any soft- tissue 
shifts >1 cm as it can impact on the accuracy of the 
expected dosimetry. If shifts over 1 cm occur, they 
should be discussed with the planning department 
and RTTQA should be contacted following treatment.
v. Manual moves should be undertaken if further opti-
misation of PTV2 coverage can be achieved. Manual 
moves prioritising coverage to the boost region over 
the normal bladder wall is permitted if it avoids ex-
cessive normal tissue irradiation that would have oc-
curred by selecting a larger plan.
vi. Finally, the OARs as seen on the CBCT is reviewed 
and compared with the position on the planning CT. 
The position of OARs relative to the boost is assessed 
to ensure that excessive normal tissue does not sit 
within the PTV2, especially for DART patients. If this 
is the case, manual move is permitted to minimise 
normal tissue irradiation but should not be at the ex-
pense of target coverage.
vii. A second accredited radiographer or practitioner 
must confirm selected plan and any additional ac-
tions taken. Once agreement has been reached, any 
necessary couch correction is performed prior to 
treatment delivery with the selected plan.
Fractions must not be omitted or missed due to unfa-
vourable positioning of normal anatomy such as rectal 
distention due to flatus or faeces. Additional guidance 
and potential solutions are provided for scenarios that 
may arise on treatment are given in the radiotherapy 
planning and delivery guidelines (online supplemental 
appendix 2, p. 45). The flow chart of potential inter-
ventions is derived from phase I experience previously 
published.28
For example, if the bladder is significantly smaller 
than the CTV_30 contour at planning, it is likely that the 
PTV2 boost will be in the incorrect position and, or does 
not achieve adequate normal bladder sparing. In these 
circumstances, patients should be removed from the 
treatment couch, and encouraged to fill the bladder by 
drinking further, and or increasing the time interval of 
image acquisition.
In the event that the bladder has overfilled and none 
of the PTVs provides adequate coverage despite manual 
moves, the patient should be asked to minimally void 
Table 5 Organ at risk dose constraint guide
Normal tissue
32 fraction cohort 20 fraction cohort
Constraint Optimal Mandatory Constraint Optimal Mandatory
Rectum V30Gy 80% V25Gy 80%
V50Gy 60% V41.7Gy 60%
V60Gy 50% V50Gy 50%
V65Gy 30% V54.2Gy 30%
V70Gy 15% V58.3Gy 15%
Femoral heads V50Gy 50% V41.7Gy 50%
Other bowel V45Gy 116cc 139cc V37.5Gy 116cc 139cc
V50Gy 104cc 127cc V41.7Gy 104cc 127cc
V55Gy 91cc 115cc V45.8Gy 91cc 115cc
V60Gy 73cc 98cc V50Gy 73cc 98cc
V65Gy 23cc 40cc V54.2Gy 23cc 40cc
V70Gy 0cc 10cc V58.3Gy 0cc 10cc







40% only in DART
Otherwise 0% in 
SART
80%






40% only in DART
Otherwise 0% in 
SART
80%
50% only in DART
Otherwise 5% 
SART
Body- PTV (normal 
tissue)








*Whole bladder (CTV) constraint specified should be used to inform plan optimisation. Bladder outside PTV2 (ie, CTV- PTV2) meeting these 
contraints will also be collected for reporting of the primary end point.
CTV, clinical target volume; DART, dose- escalated adaptive tumour- focused radiotherapy; PTV, planning target volume; SART, standard dose 
adaptive tumour- focused radiotherapy.
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and the CBCT is repeated. If this is not possible, patient 
should void completely and restart drinking protocol 
with a reduction in the time interval for CBCT acquisi-
tion. In these circumstances, a member of the clinical 
team should also be notified to ensure the patient is not 
in urinary retention.
When amending the drinking protocol to optimise 
patient’s anatomy to fit the existing PTV contours, it 
is advised that one aspect is changed at a time, that is, 
interval for CBCT acquisition timing or the amount of 
water that is drunk. This is so the impact of the interven-
tion can be determined and altered for subsequent frac-
tions as required.
If no PTV contours are suitable to cover the target 
because of rectal gas, then the patient should be removed 
from the bed and ask to void. The CBCT image acquisi-
tion is then repeated. If the PTV contours still are not 
optimal, it is recommended that the most suitable plan 
is selected which optimises coverage of PTV2 and mini-
mises the inclusion of OARs is chosen for treatment. If 
this occurs repeatedly (eg, more than twice in five frac-
tions) RTTQA should be contacted for advice.
All CBCT exposures including those not resulting in 
treatment should be recorded on the CRF and plan selec-
tion form.
In all randomised groups, a post- treatment CBCT 
should be taken during the first week and once a week 
thereafter. This CBCT should be reviewed locally to 
ensure intrafraction filling has been accommodated for 
at the time of plan selection.
Radiotherapy protocol compliance programme
The RAIDER trial is subject to radiotherapy QA 
programme that aims to standardise contouring, plan-
ning and delivery of image- guided and adaptive bladder 
radiotherapy in participating centres. The RTTQA group 
coordinates the UK QA programme for the study. For 
Australian and New Zealand participants, this is coordi-
nated by the TROG QA Team.
The QA programme has a pretrial and on- trial compo-
nent. Each centre will be required to complete the pre- 
trial QA prior to commencing recruitment.
Prior to trial entry, participating centres will be asked 
to complete a facility questionnaire in order to gauge 
current local IGRT experience. A separate process docu-
ment is used to collect task details of all aspects of a 
complete patient pathway.
The PI at each participating site is asked to contour 
two benchmark clinical cases as per protocol. One case 
includes tumour bed GTV as defined by placement of 
fiducial markers (radio- opaque contrast agent, lipiodol). 
UK PIs who completed outlining benchmark cases for 
the preceding phase II adaptive bladder radiotherapy 
trial (HYBRID Trial, NCT01810757) will be asked to 
contour only the target volumes as the OARs contouring 
is unchanged for the RAIDER protocol.31 Structured 
feedback to the PI will be provided via RTTQA team.
All participating trial centres will also be required to 
complete a planning benchmark case. Centres will be 
provided with access to CT DICOM data and preout-
lined structure set. They will be requested to the plan 
this patient in their own treatment planning system as 
if randomised to the DART arm. It is the responsibility 
of the local investigator to ensure that appropriate plan 
checking QA process is in place at their local institu-
tion. Once the three plans of the benchmark case have 
been created, reviewed and accepted by the local PI, the 
DICOM CT, dose cubes, RTplan and structure sets are 
returned to the RTTQA team and structured feedback is 
provided.
It is a pretrial requirement that all participating centres 
have both an established IGRT training programme in 
place for their radiographers and be using CBCT to assess 
bladder treatment delivery. Trial- specific bladder IGRT 
competency will be completed through an online plan 
selection training package, and practical workshop.32
The online plan selection training consists of two 
practice cases each with six CBCTs to work through. 
Step- by- step instructions with correct plan selections 
is provided. Following this, a credentialing assessment 
consisting of 12 plan selections will be carried out. The 
plan selections and matched reviews will be assessed by 
RTTQA and structured feedback provided. Only those 
who meet minimum threshold of concordance of plan 
selection as predefined by the trial team will be approved 
for performing RAIDER plan selection. Those who were 
accredited for plan selection in the HYBRID study31 or in 
the TROG 10.1 BOLART trial training (NCT01142102)33 
will not be asked to repeat this assessment.
As part of the on- trial QA, the contouring and planning 
of at least the first adaptive patient and the first DART 
will be subject to prospective review by the RTTQA group.
All planning data and treatment delivery data including 
paired weekly pretreatment and post- treatment CBCTs, 
registration objects and treatment forms will be collected 
and reviewed retrospectively by the RTTQA group to 
ensure adherence to the RAIDER planning and delivery 
protocol is maintained. Remote retrospective plan selec-
tion review will take place for adaptive radiotherapy 
patients during the trial.
Statistical considerations
The primary aim of the study is to evaluate the feasibility 
(stage I) and safety (stage II) of DART. Control (WBRT) 
and SART treatment groups are included to enable SART 
to be carried forward to stage II if dose constraints cannot 
be met in the DART group and to assess equipoise and 
feasibility of recruitment for any subsequent phase III 
trial. Prospectively collected contemporaneous toxicity 
data for WBRT and SART will also allow benchmarking 
of DART results. Patients are randomised 1:1:2 to maxi-
mise information on DART. Recruitment to stage II will 
continue seamlessly while stage I is evaluated, unless 
advised otherwise by the Independent Data Monitoring 
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Committee (IDMC). Patients recruited in stage I will 
contribute to analysis of stage II.
The sample size of stage I is based on proportion of 
patients allocated to DART meeting the predefined dose 
constraints of bladder, bowel and rectum on the medium 
plan. A patient in the 32f cohort will be defined as 
meeting the dose constraints if all mandatory constraints 
of the following are met for the medium plan: rectum 
constraints at 50 Gy, 60 Gy, 65 Gy and 70 Gy; bladder 
outside PTV2 at 60 Gy and 65 Gy and small bowel at V55, 
V60, V65, V70 and V74. A patient in the 20f cohort will be 
defined as meeting the dose constraints if all mandatory 
constraints of the following are met for the medium plan: 
rectum constraints at 41.7 Gy, 50 Gy, 54.2 Gy and 58.3 Gy; 
bladder outside PTV2 at 50 Gy and 54.2 Gy and bowel at 
V45.8, V50, V54.2, V58.3 and V61.7.
It is expected that in 80% of DART patients the 
predefined dose constraints of the medium plan to the 
normal bladder, bowel and rectum will be met. If this 
proportion is <50%, it will be concluded that DART 
delivery is not feasible. Using an A’Hern single stage 
design (p0=0.5, p1=0.8, 5% alpha and 80% power), 18 
patients are required in each DART fractionation cohort. 
If at least 13/18 meet dose constraints, it will be concluded 
that DART treatment is feasible; if dose constraints are 
not met for six or more patients in either fractionation 
cohort, the IDMC will advise on continuation of the trial 
with the option of dropping the DART arm in one or 
both fractionation cohorts and continuing to stage II with 
randomisation to WBRT versus SART. Stage I will there-
fore require a total of 72 patients (36 in each fraction-
ation cohort) randomised 1:1:2 between WBRT, SART 
and DART.
There are no formal early stopping rules for acute 
toxicity or efficacy but if after six patients have been 
treated per fractionation cohort, >50% of patients 
experience acute >grade 3 treatment- related toxicity, 
the IDMC would be asked to advise on suitability of 
continuation.
Stage II has a non- comparative design aiming to rule 
out an upper limit of any late ≥grade 3 CTCAE toxicity in 
each DART fractionation cohort. To be considered eval-
uable for the primary end point of late toxicity, a patient 
must receive at least one fraction of allocated treatment 
and have at least one toxicity assessment performed 
between 6 and 18 months after completing radiotherapy. 
It is expected that the proportion of patients in the 
control group reporting >grade 3 toxicity CTCAE toxicity 
between 6 and 18 months postradiotherapy will be 8%.20 
Again using an A’Hern single stage design (p0 (toxicity 
free)=0.80, p1=0.92, 5% alpha and 80% power), 57 
patients in each DART fractionation cohort will allow a 
>20% >grade 3 toxicity CTCAE toxicity to be excluded. 
If more than >6/57 evaluable DART patients experience 
≥grade 3 toxicity in either fractionation cohort, then the 
late toxicity threshold will be exceeded and on the IDMC’s 
recommendation the trial could either be stopped or the 
DART arm dropped.
Allowing for 5% non- evaluability for late toxicity by 18 
months gives a sample size of 120 patients (30 WBRT, 30 
SART, 60 DART) for each fractionation cohort, that is, a 
total target sample size of 240. The non- evaluability rate 
will be monitored and, with IDMC endorsement, cohort 
recruitment will continue until there are 57 evaluable 
DART patients per cohort. During stage II, following 
IDMC review, consideration would be given to dropping 
the WBRT or SART arms, if it was felt sufficient data had 
accrued for these arms and it would expedite meeting the 
aims of the trial. The IDMC will also monitor recurrence 
rates. If an absolute excess of locoregional recurrence is 
seen, early termination of the trial would be considered.
For stage I, the primary end point will be presented as 
the frequency and percentage of randomised patients 
able to meet the trial dose constraints in the DART group. 
For stage II, the primary end point will be based on the 
evaluable population. The proportion of patients with any 
>grade 3 CTCAE toxicity occurring within 6–18 months 
postradiotherapy will be presented for each randomised 
treatment group together with the 90% one- sided bino-
mial CI (the 90% two- sided CI will also be presented). A 
sensitivity analysis will be conducted using a per- protocol 
population. The per- protocol population will include 
evaluable patients who received their complete fraction-
ation schedule (either 32f or 20f) according to their 
randomised allocation group.
The local control rate at 2 years will be presented by 
treatment group with a 95% CI. Acute and late toxicity 
will be summarised by frequencies and proportions 
at each time point by treatment group. Kaplan- Meier 
methods will also be used to analyse time to local disease 
progression and overall survival with data presented by 
randomised group.
ETHICS AND DISSEMINATION
The trial is approved by the London- Surrey Borders 
Research Ethics Committee (15/LO/0539).
The first participant was enrolled in October 2015. The 
study recruitment is scheduled to complete in Spring 
2020. It is expected that the trial will report in 2022, 
following which the results will be disseminated via peer- 
reviewed scientific journals, conference presentations 
and submission to regulatory authorities.
Safety reporting
Data are collected at each trial visit regarding any adverse 
events graded according to CTCAE V.4 criteria on the 
CRF. The highest grade observed since the last visit should 
be reported. All serious adverse events (SAEs) occurring 
from the start of radiotherapy up to 30 days following the 
last fraction and any radiotherapy- related >grade 3 events 
occurring between 6 and 18 months are reported to the 
ICR- CTSU within 24 hours of the PI becoming aware 
of the event. SAEs should be followed up until clinical 
recovery is complete or until the condition has stabilised. 
Any safety concerns will be reported to the main research 
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and ethics committee by ICR- CTSU as part of the annual 
progress report.
Trial monitoring and oversight
A Trial Management Group (TMG) will be set up and will 
include the Chief Investigator, ICR- CTSU Methodology 
Lead, co- investigators, identified collaborators, the trial 
statistician, trial manager and patient representative.
The ICR- CTSU Urology Radiotherapy Trials Steering 
Committee (TSC) includes a chairperson not directly 
involved in the trial, and at least two other independent 
members who will oversee the RAIDER trial. The TSC will 
meet annually.
An IDMC will be set up to monitor the progress of the 
trial and will include at least three independent members, 
one of whom will be a medical statistician. The Commit-
tee’s terms of reference, roles and responsibilities will be 
defined in a charter issued by ICR- CTSU. The IDMC will 
meet in confidence at regular intervals, and at least annu-
ally. A summary of findings and any recommendations 
will be produced following each meeting. This summary 
will be submitted to the TMG and TSC, and if required, 
the main REC.
Patient and public involvement
The RAIDER trial has been reviewed and endorsed by 
patient and carer representatives from the National 
Cancer Research Institute (NCRI) Consumer Liaison 
Group and the NCRI Clinical and Translational Radio-
therapy Research Group (CTRad) working group. The 
CTRad consumer group also approved the proposal 
for randomisation ratio to be weighted towards partici-
pants receiving advanced radiotherapy techniques.
Patient and public involvement began at the protocol 
design and development stage via national and local 
consumer oversight committee review. This included the 
NIHR Biomedical Research Centre radiotherapy studies 
consumer panel at The Institute of Cancer Research 
and The Royal Marsden NHS Foundation Trust, and the 
NCRI Bladder Clinical Studies Group, which includes 
consumer representation.
Patients who had participated in the phase I bladder 
radiotherapy studies25 28 were asked to assess if the 
burden of involvement required for participation was 
appropriate. This included review of the patient- reported 
outcomes questionnaires.
The trial patient information sheet and consent 
form were reviewed by the South West London Cancer 
Research Network consumer group. Their feedback 
was adopted and incorporated into the final version 
of both documents. Copy of the ethics approved 
final version of the patient information sheet and 
consent form are provided in the online supplemental 
appendix 3.
Patient representation on the TMG advises on day- 
to- day management of the trial including patient 
recruitment, and it is expected that they will also 
participate in dissemination of results via bladder 
cancer patient groups.
CONCLUSIONS
RAIDER represents the first randomised trial of dose- 
escalated adaptive tumour- focused ‘plan of the day’ 
radiotherapy and provides a framework for multicentre 
implementation of this technique. It seeks to investigate 
whether this approach will allow an increase of radia-
tion dose to be delivered to the tumour with acceptable 
toxicity. Results will inform the design of a future phase 
III trial to establish the optimum organ preserving treat-
ment option for patients with MIBC.
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RAIDER TRIAL SUMMARY 
PROTOCOL TITLE A Randomised phase II trial of Adaptive Image guided standard or Dose 
Escalated tumour boost Radiotherapy in the treatment of transitional 
cell carcinoma of the bladder  
TARGET DISEASE Muscle invasive bladder cancer 
STUDY OBJECTIVES To define a feasible and safe adaptive dose escalated tumour boost 
radiotherapy schedule for MIBC; to investigate the ability to deliver daily 
adaptive bladder radiotherapy and assess the impact of delivery on 
patient reported outcomes and health economic related measures. 
STUDY DESIGN Multicentre two stage, three arm phase II randomised controlled trial 
TRIAL POPULATION Patients receiving radical radiotherapy for muscle invasive bladder cancer 
RECRUITMENT TARGET Minimum 120 in each of two fractionation cohorts i.e. sufficient to accrue 
57 evaluable DART patients per cohort. 
TRIAL TREATMENT Patients will be randomised (1:1:2) between: 
1. Standard whole bladder radiotherapy delivery (WBRT) (control) 
2. Standard dose Adaptive tumour focused radiotherapy (SART) 
3. Dose escalated Adaptive tumour boost radiotherapy (DART) 
64Gy/32f and 55Gy/20f fractionation schedules are permitted. 
Participants in all groups will be permitted to receive concomitant 
radiosensitising therapy. Full blood count (FBC), urea and electrolytes 
(U&Es) and acute toxicity will be assessed during radiotherapy.  
Participants in the Patient Reported Outcomes (PRO) sub-study will be 
asked to complete a questionnaire prior to trial entry and at the end of 
radiotherapy.  
PRIMARY ENDPOINT Stage I: Proportion of patients meeting radiotherapy dose constraints to 
bladder, bowel and rectum in DART groups. 
Stage II: Proportion of patients experiencing any ≥Grade 3 Common 
Terminology Criteria for Adverse Events (CTCAE) v.4 late toxicity (6-18 
months post radiotherapy). 
SECONDARY ENDPOINTS Stage I:  
 Recruitment rate 
 Ability to deliver SART and DART 
Stage II: 
 Clinician reported acute toxicity 
 PRO: acute and late bladder and bowel/rectal symptoms;  
 Health economic related measures: time for outlining, plan 
generation, selection and delivery, NHS resource usage 
subsequent to treatment;  
 Loco-regional MIBC control 
 Progression-free survival 
 Overall survival 
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EXPLORATORY ENDPOINTS 
 
Image Guided Radiotherapy (IGRT) endpoints: 
 Use of adaptive plans 
 Target coverage 
 Online/offline concordance 
 Dose volume analysis of adaptive vs. standard planning 
FOLLOW UP Participants will subsequently be assessed at the following intervals: 
6 weeks from start of radiotherapy (20f cohort only) 
Assessment of acute toxicity (CTCAE v.4) 
10 weeks from start of  radiotherapy: 
Assessment of acute toxicity (CTCAE v.4) 
3 months from end of radiotherapy: 
Rigid cystoscopy and biopsy of tumour bed, FBC, U&Es, chest x-ray (CXR), 
acute toxicity (CTCAE), PRO questionnaire (if participating in sub-study). 
6 months from end of radiotherapy: 
Flexible cystoscopy, FBC, U&Es, CXR or CT chest, CT abdomen and pelvis, 
late toxicity (CTCAE, RTOG), PRO (if participating in sub-study) 
9 months from end of radiotherapy: 
Flexible cystoscopy, late toxicity 
12 months from end of radiotherapy: 
Flexible cystoscopy, CT abdomen and pelvis, CXR or CT chest, late toxicity, 
PRO (if participating in sub-study) 
18 months from end of radiotherapy: 
Flexible cystoscopy, CXR or CT chest, late toxicity, PRO (if participating in 
sub-study) 
24 months from end of radiotherapy: 
Flexible cystoscopy, CT abdomen and pelvis, CXR or CT chest, late toxicity, 
PRO (if participating in sub-study) 
Yearly to year 5: Flexible cystoscopy, CXR or CT chest, late toxicity 
Annually thereafter: Survival and disease status 
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they simply no longer wish to attend trial follow up visits. In the very rare event that a patient requests that 
their data is removed from the study entirely, the implications of this should be discussed with the patient 
first to ensure that this is their intent and, if confirmed, ICR-CTSU should be notified in writing. The patient 
should be made aware that any information about them that has already been published or submitted for 
safety monitoring purposes cannot be withdrawn.  
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will be held under the custodianship of the Trial Management Group on behalf of the sponsor. Translational 
analyses will be conducted at a later date once appropriate funding has been secured.  
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A1. WHO PERFORMANCE STATUS 
Grade  Performance Status 
0 Able to carry out all normal activity without restriction. 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
light work. 
2 Ambulatory and capable of all self-care but unable to carry out any work; up and 
about more than 50% of waking hours. 
3 Capable of only limited self-care; confined to bed or chair more than 50% of 
waking hours. 
4 Completely disabled; cannot carry on any self-care; totally confined to bed or 
chair. 
 
A2. RTOG/EORTC LATE RADIATION MORBIDITY SCORING SCHEMA 
0 1 2 3 4 5 
BLADDER      



































     
None Mild diarrhoea 
Mild cramping 
Bowel movement 
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A3. TUMOUR LOCALISATION GUIDELINES 
For radiotherapy planning the delineated bladder tumour will be defined using all pre-treatment diagnostic 
imaging, surgical bladder map and the placement of fiducial markers if possible (see Radiotherapy Planning 
and Delivery Guidelines).  
A3.1 Fiducial marker placement  
Prior to radiotherapy, where possible fiducial marker insertion (gold seed or Lipiodol) into the bladder wall 
surrounding the tumour should be considered. Only patients medically fit to undergo a general anaesthetic 
should be considered for gold seed insertion. Only patients fit for general anaesthetic and without a history 
of contrast medium sensitivity or active thyroid disease should be considered for Lipiodol insertion. 
The fiducial markers are inserted into the bladder wall to demarcate the maximum extent of visible tumour 
or tumour bed. Gold seeds need to be inserted via a customised introducer.   
The recommended procedure for Lipiodol injection is 
1. Undertake cystoscopy under general anaesthetic performing a cystourethroscopy with visual 
mapping of scars and lesions. Record details on trial proforma. Measure bladder volume. If 
required biopsy scar plus/minus random biopsy. 
2. Lipiodol is inserted using a 5 French ‘Botox’ needle. 
3. Draw up 5 mls of Lipiodol 
4. With the bladder full, inject 0.5 mls subepithelially 2cms away from scar or residual tumour. 
Use 4-6 injections circumferentially around scar. Do not exceed injection volume as this can 
lead to pelvic leakage. 
5. Diathermy injection sites to prevent Lipiodol leaking back out 
6. Record details of procedures on bladder map, make note of number of injections, position 
and distance from scar. 
Fiducial marker placement is unlikely to result in side effects over and above the toxicities associated with 
cystoscopy +/- general anaesthetic.  
A3.2 Surgical bladder map 
At the time of cystoscopy the urologist will be ask to localise the tumour (size and position) on a surgical 
bladder map to aid tumour localisation for radiotherapy planning.  
A3.3 Training and quality assurance 
A video demonstrating the fiducial marker placement technique will be available on the ICR-CTSU website.  
Each centre will be requested to nominate a lead surgeon providing oversight of fiducial marker placement 
for RAIDER trial participants (if using).  Lead surgeons will be asked to provide details of their centres’ fiducial 
marker placement experience and to provide assurance that those placing fiducial markers have completed 
the required training.  
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A4. PATIENT REPORTED OUTCOMES STUDY 
A4.1 Background 
Patient reported outcomes (PRO) are a key secondary endpoint within RAIDER.  PRO within RAIDER will focus 
on the impact of bladder radiotherapy on symptoms experienced by patients.  The aim will be to collect 
detailed information about the impact of bladder radiotherapy on participants’ daily lives, with a focus on 
side effects being experienced but also including a measure of general wellbeing. 
The objective of the PRO sub-study within RAIDER is to compare the impact of adaptive planned radiotherapy 
on side effects as reported by the participants.  This will help to support any differences in toxicity established 
within the primary endpoint of clinician reported toxicity.  In addition, PRO data will be compared with 
clinician reported toxicity to give an indication of the concordance of the two measures. 
A4.2 Hypotheses 
1.  SART minimises treatment toxicity and improves patient reported symptoms /quality of life 
2.  DART is tolerated well and has no or minimal impact on patients’ reported experiences 
A4.3 Quality of life measures 
Patient reported outcomes will be measured using the PRO-CTCAE™ questionnaire, King’s Health 
Questionnaire (KHQ), sexual function questions, ALERT-B and the EQ-5D. 
PRO-CTCAE is a patient-reported outcome measure developed to evaluate the frequency, severity and 
interference of symptomatic toxicity in patients on cancer clinical trials.  It was designed to be used as a 
companion to the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE includes an item 
library representing symptomatic toxicities drawn from the CTCAE. Items selected for inclusion relate to 
gastrointestinal symptoms (41).  
Urinary side-effects experienced by participants will be captured using the KHQ, which has been validated 
for use in patients with overactive bladder(42) and captures details of the severity of symptoms and the 
impact of urinary incontinence on day to day living.  Impact on sexual function will be assessed using an 
excerpt of the EORTC QLQ-BLM30, a muscle invasive bladder cancer specific questionnaire (43). 
Participants will also be asked to complete the EQ5D questionnaire, a brief standardised instrument which 
provides a simple descriptive profile of health status (44) and the three-item ALERT-B Questionnaire which 
provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in 
cancer survivors (45). 
A4.4 Study design 
Patients are eligible for the PRO study if they fulfil the RAIDER eligibility criteria.  Participants will be asked in 
the patient information sheet to consent to regular completion of PRO questionnaires.  Patients who decline 
to take part in the RAIDER PRO study will remain eligible for the main trial.  PRO is a secondary endpoint in 
the main trial and the primary timepoint of interest is 18 months after completion of radiotherapy. 
A4.5 Timing of data collection 
Participants will be asked to complete a questionnaire in clinic within 2 weeks prior to the start of 
radiotherapy.   Further questionnaires will be completed in clinic at the end of treatment delivery and 3 
months from the end of treatment.  Four further booklets will be sent to participants’ homes by ICR-CTSU at 
6, 12, 18 and 24 months from the end of treatment. 
A4.6 Compliance 
Missing data may hamper interpretation of PRO. Missing data may arise because participants do not 
complete the questionnaires at the appropriate time (unit non-response), or because patients may miss 
questions within the questionnaires (item non-response).  In a population of patients with low performance 
status such as those included in RAIDER, there is potential for non-response and informative censoring (with 
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data not missing at random).  During the study, compliance with PRO questionnaire completion will be 
monitored by the trial oversight committees. 
A4.7 Statistical considerations 
Patient reported outcome analyses will be used to supplement results of clinician assessed treatment 
toxicity, therefore a formal sample size calculation has not been performed.  An analysis plan will be 
developed in consultation with the TMG with key endpoints identified from each questionnaire.  Standard 
algorithms will be used to derive scores and handle missing data in quality of life questionnaires.  Quality of 
life data will be presented at individual time-points and analyses to account for the longitudinal nature of the 
data may be used. 
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A5. EXPECTED SERIOUS ADVERSE EVENTS 
Hospitalisation for any of the following adverse events is exempt from expedited reporting if the event is 
grade 2 or less:  




 Bladder spasms or pain 
 Diarrhoea 
 Constipation 
 Abdominal pain 
 Urinary tract infection 
 Urinary/clot retention 
 Fatigue 
 Neutropaenia (related to concomitant chemotherapy) 
 Thrombocytopaenia (related to concomitant chemotherapy) 
 Neutropaenic sepsis (related to concomitant chemotherapy) 
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FORWARD 
The Trans Tasman Radiation Oncology Group (TROG) has been authorised by the Institute of Cancer Research 
(ICR) to undertake a coordinating role for participants enrolled in Australia and New Zealand on this trial.  
The involvement of TROG necessitates a number of changes to the procedures documented in the main body 
of the RAIDER protocol. The following sections have been adjusted for TROG trial sites and participants and 
replace, or add to, the above RAIDER protocol sections where relevant. 
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TROG trial sites in Australia and New Zealand shall report SAEs within 24 hours of the Principal Investigator 
(or designated representative) becoming aware of the event, by completing the RAIDER SAE form and faxing 
to: 
The TROG Central Operations Office 
Fax no: 0061 2 4014 3902 
As much information as possible, including the Principal Investigator’s assessment of causality, must be 
reported to the TROG TCC in the first instance.  Additional follow up information should be reported as soon 
as it is available. 
All SAE forms must be completed, signed and dated by the Principal Investigator or designated 
representative. 
The Site SAE log should be completed and the SAE form filed in the Site Investigator File. 
A6.4 Review of serious adverse events 
Replaces section 12.5 of the protocol 
The TROG Trial Chairperson (or designated representative) will assess all reported SAEs for Australian and 
New Zealand (ANZ) sites for causality and expectedness (NB. The TROG Trial Chairperson cannot down-grade 
the Principal Investigator’s assessment of causality.) 
SAEs assessed as having a causal relationship to study treatment and as being unexpected will undergo 
expedited reporting to the relevant regulatory authorities and all other interested parties by the TROG TCC 
(see 3.3).  
Sites should respond as soon as possible to requests from the TROG Trial Chairperson or designated 
representative (via TROG) for further information that may be required for final assessment of an SAE.  ICR-
CTSU will be provided with details of every reported SAE once final assessment is completed. 
A6.5 Expedited reporting of related unexpected SAEs 
Replaces section 12.6 of the protocol 
If an SAE is identified as being related and unexpected by the TROG Trial Chairperson it will be reported by 
the TROG TCC to the lead Human Research Ethics Committee (HREC), the Sponsor (via ICR-CTSU) and all other 
interested parties within each parties’ reporting timelines. 
The Principal Investigators at all actively recruiting sites will be informed of any related unexpected SAEs 
occurring within the trial at appropriate intervals. 
A6.6 Follow up of serious adverse events 
Replaces section 12.7 of the protocol 
SAEs should be followed up until clinical recovery is complete or until the condition has stabilised.  SAE 
outcomes should be reported to the TROG TCC using the relevant section of the SAE form as soon as the 
Principal Investigator or designee becomes aware of the outcome.  
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To provide protection for trial participants involved in TROG Clinical Trials, TROG maintains a clinical trials 
insurance policy.  
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A7. GLOSSARY 
AE  Adverse Event 
APPLY  Adaptive predictive planning for 
hypofractionated bladder 
radiotherapy 
CBCT   Cone Beam CT 
CI  Chief Investigator 
CI  Confidence Interval 
CIS  Carcinoma In Situ 
CRF  Case Report Form 
CT   Computed Tomography 
CTCAE   Common Terminology Criteria for 
Adverse Events 
CTV   Clinical Target Volume 
CXR  Chest X-Ray 
DART  Dose escalated Adaptive tumour 
focused Radiotherapy 
DCF  Data Capture Form 
DVH  Dose Volume Histogram  
dwMRI  Diffusion weighted Magnetic 
resonance  Imaging 
EORTC  European Organisation for 
Research and Treatment of 
Cancer  
f  Fraction 
FBC  Full Blood Count 
GI  Gastrointestinal 
GSA Group Specific Addendum 
GTV  Gross Tumour Volume 
GU  Genitourinary 
Gy  Gray 
HR  Hazard Ratio 
ICR  The Institute of Cancer Research 
ICR-CTSU  The Institute of Cancer Research 
Clinical Trials and Statistics Unit 
IDMC  Independent Data Monitoring 
Committee 
IGRT   Image Guided Radiotherapy 
IMRT  Intensity Modulated 
Radiotherapy 
KHQ  King’s Health Questionnaire 
MDT  Multi-Disciplinary Team 
MIBC   Muscle Invasive Bladder Cancer 
MRI   Magnetic Resonance Imaging 
NCRI   National Cancer Research 
Institute 
NCRI RTTQA  NCRI Radiotherapy Clinical Trials 
Quality Assurance group 
NICE   National Institute for Health and 
Clinical Excellence  
NSAID  Non-Steroidal Anti-Inflammatory 
Drug 
PI  Principal Investigator 
PIS  Patient Information Sheet 
PRO   Patient Reported Outcomes 
PTV   Planning Target Volume 
QA  Quality Assurance 
R&D  Research and Development 
REC   Research Ethics Committee 
RMH   Royal Marsden Hospital 
RT   Radiotherapy 
RTOG   Radiation Therapy Oncology 
Group 
RTTQA  Radiotherapy Trials Quality 
Assurance  
SAE  Serious Adverse Event 
SAR  Serious Adverse Reaction 
SART  Standard dose Adaptive tumour 
focused Radiotherapy 
TCC  Transitional Cell Carcinoma 
TMG  Trial Management Group 
TSC  Trial Steering Committee 
TURBT  Transurethral resection of 
Bladder Tumour 
U & Es  Urea and Electrolytes 
WHO  World Health Organisation 
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VERSION CHANGES 
V1.0 - Original RT planning and delivery guidelines 
V2.0 – RT planning and delivery guidelines updated to include TROG QA appendix and contact details. 
V3.0- The following changes have been made: 
 Section 2.4 (Pg 11) and Section 5 (Pg 20)- Clarification provided on what CT30 and CT60 are to be used 
for 
 Section 5 Table 4 & 5 (Pg 21/22)- Clarification regarding  which target volumes the dose objectives are 
for 
 Section5: Table 5 (Pg 22)- D50% +/- 1% for PTV2 moved from “Optimal” to “Mandatory” 
 Section 5.5 (Pg 24/25)- Planning recommendations added based on pre-trial QA exercise 
 Section 7.4 (Pg 28)- Recommendations for  exporting CBCT data from Aria/Mosaiq 
 Appendix A: QA Programme UK – Pre-trial point 7: IGRT training video now provided 
 Appendix B: TROG QA Programme- QA programme updated with IGRT training/assessment 
information 
V4.0- The following changes have been made: 
 Section 1 (Pg 10) Clarification on the start date of radiotherapy 
 Section 2.3 (Pg 11) Clarification on contrast. Contrast is permitted; however it is recommended to 
perform the planning CT scan without it 
 Section 3.5 (Pg 14) Clarification on treatment volumes for each randomisation group 
 Section 3.6 (Pg 16) NEW voluming checklist with clarification on outlining the GTV and CTV 
 Section 3.7 (Pg 20) Nomenclature table updated 
 Section 4 (Pg 22) Clarification on actions to take when replanning required 
 Section 4.3 (Pg 2) Clarification on target dose objectives, with emphasis placed on PTV2 
 Section 4.4 (Pg 24) Clarification on normal tissue dose constraints 
 Section 4.4 (Pg 24/25) Table 6a and 6b updated to include new optimisation targets for the CTV 
 Section 4.5 (Pg 25) Planning recommendations updated, with emphasis placed on PTV2 
 Section 4.6 (Pg 26) Further clarification and guidance for pre-treatment checks 
 Section 5 (Pg 27) Treatment delivery updated 
 Section 5.2 (Pg 27/28) NEW guidance on Adaptive Tumour Focused Radiotherapy (SART & DART) 
 Section 5.2.1 (Pg 27/28) NEW plan selection steps 
 Sections 5.2.2 (Pg 28) NEW plan selection tips 
 Section 5.3 (Pg 28) Clarification on post-treatment CBCTs 
 Appendix A: QA Programme UK 
o On trial QA updated – site visits removed and IGRT/POD selection support introduced 
o Clarification on data export 
o NEW Table 7: RAIDER data checklist 
 Appendix B: TROG QA Programme 
o On trial QA updated to include IGRT/POD selection support 
 Appendix C: QA Benchmark Cases for Outlining and Planning moved to Appendix C 
o Additional diagnostic information for outlining case 1 included (NEW) 
 Appendix D: Quick Contouring Checklist (NEW) 
 Appendix E: Clarification on treatment interventions 
 Appendix F: Text updated to be in line with Section 5.2 
 Appendix G: Quick Reference Guide for Exporting CBCTs from ARIA (NEW) 
 Appendix H:  Quick Reference Guide for Exporting CBCTs from MOSAIQ (NEW) 
V4.1- The following changes have been made: 
 Section 4.4: Clarification on updated (V4.0) Normal Tissue Dose Constraints 
V4.2 - The following changes have been made: 
 Front cover updated  (Pg 1/2) RAIDER Guidelines only to be used for the purpose of RAIDER 
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 Trial Management Details (Pg 3) ICR-CTSU contact details upated 
 RAIDER TRIAL SUMMARY (Pg 7) Recuitment Target updated 
 Trial Schema (Pg 9) Updated 
 Section 1 (Pg 10) A list of RAIDER QA credentialed staff must retained in site investigator file 
 Section 4.4 (Pg 24) Clarification do not compromise dose to PTV2 or PTV in order to meet the normal 
tissue dose constraints 
 Section 5.2.1 (Pg 27-28) Clarification on Image Match and Plan Selection Steps: 
o Consider magnitude of soft tissue shift and review if over 1cm 
 Section 5.2.2 (Pg 28-29) Clarification on Image Match and Plan Selection Tips: 
o Fractions must not be omitted or missed due to unfavourable positioning of normal 
anatomy 
o Review post-treatment CBCTs for intrafraction filling 
 Section 6 (Pg 29-30) Clarification on Treatment Scheduling and Gaps: 
o Avoid gaps where possible 
o Further guidance when staff unavailable/machine breakdown 
o Compensation not expected due to toxicity 
o Involved PI 
 Appendix G (Pg 50) Additional information for Aria Export 
V4.3 - The following changes have been made: 
 Appendix A (Pg 33) Data transfer details updated for RTTQA 
 Appendix B (Pg 37) Data export and upload updated for TROG 
 Appendix G (Pg 51) Please contact RTTQA for information on suitable anonymization software for 
CBCTs from ARIA 
 Appendix I (Pg 53) Please contact RTTQA for information when exporting CBCTs from Raystation 
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RAIDER TRIAL SUMMARY 
PROTOCOL TITLE A Randomised phase II trial of Adaptive Image guided standard or Dose 
Escalated tumour boost Radiotherapy in the treatment of transitional 
cell carcinoma of the bladder 
TARGET DISEASE Muscle invasive bladder cancer 
STUDY OBJECTIVES To define a feasible and safe adaptive dose escalated tumour boost 
radiotherapy schedule for MIBC; to investigate the ability to deliver 
daily adaptive bladder radiotherapy and assess the impact of delivery 
on patient reported outcomes and health economic related measures. 
STUDY DESIGN Multicentre two stage, three arm phase II randomised controlled trial 
TRIAL POPULATION Patients receiving radical radiotherapy for muscle invasive bladder 
cancer 
RECRUITMENT TARGET Minimum 120 in each of two fractionation cohorts i.e. sufficient to 
accrue 57 evaluable DART patients per cohort 
TRIAL TREATMENT Patients will be randomised (1:1:2) between: 
1. Standard whole bladder radiotherapy delivery (WBRT) (control) 
2. Standard dose Adaptive tumour focused radiotherapy (SART) 
3. Dose escalated Adaptive tumour boost radiotherapy (DART) 
64Gy/32f and 55Gy/20f fractionation schedules are permitted. 
Participants in all groups will be permitted to receive concomitant 
radio sensitising chemotherapy. Full blood count (FBC), urea and 
electrolytes (U&Es) and acute toxicity will be assessed during 
radiotherapy.  Participants in the Patient Reported Outcomes (PRO) 
sub-study will be asked to complete questionnaire prior to trial entry 
and at the end of radiotherapy.  
PRIMARY ENDPOINT Stage I: Proportion of patients meeting radiotherapy dose constraints 
to bladder, bowel and rectum in DART groups. 
Stage II: Proportion of patients experiencing any ≥Grade 3 Common 
Terminology Criteria for Adverse Events (CTCAE) v.4 late toxicity (6-18 
months post radiotherapy). 
SECONDARY ENDPOINTS Stage I:  
 Recruitment rate 
 Ability to deliver SART and DART 
Stage II: 
 Clinician reported acute toxicity 
 PRO: acute and late bladder and bowel/rectal symptoms;  
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 Health economic related measures: time for outlining, plan 
generation, selection and delivery, NHS resource usage 
subsequent to treatment;  
 Loco-regional MIBC control 
 Progression-free survival 
 Overall survival 
EXPLORATORY ENDPOINTS 
 
Image Guided Radiotherapy (IGRT) endpoints: 
 Use of adaptive plans 
 Target coverage 
 Online/offline concordance 
 Dose volume analysis of adaptive vs. standard planning 
FOLLOW UP Participants will subsequently be assessed at the following intervals: 
6 weeks from start of radiotherapy (20f cohort only) 
Assessment of acute toxicity (CTCAE v.4) 
10 weeks from start of  radiotherapy: 
Assessment of acute toxicity (CTCAE v.4) 
3 months from end of radiotherapy: 
Rigid cystoscopy and biopsy of tumour bed, FBC, U&Es, chest x-ray 
(CXR), acute toxicity (CTCAE), PRO questionnaire (if participating in sub-
study). 
6 months from end of radiotherapy: 
Flexible cystoscopy, FBC, U&Es, CXR or CT chest, CT abdomen and 
pelvis, late toxicity (CTCAE, RTOG), PRO(if participating in sub-study) 
9months from end of radiotherapy: 
Flexible cystoscopy, late toxicity 
12months from end of radiotherapy: 
Flexible cystoscopy, CT abdomen and pelvis, CXR or CT chest, late 
toxicity, PRO(if participating in sub-study) 
18months from end of radiotherapy: 
Flexible cystoscopy, CXR or CT chest, late toxicity, PRO(if participating 
in sub-study) 
24 months from end of radiotherapy: 
Flexible cystoscopy, CT abdomen and pelvis, CXR or CT chest, late 
toxicity, PRO(if participating in sub-study) 
Yearly to year 5: Flexible cystoscopy, CXR or CT chest, late toxicity 
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Annually thereafter: Survival and disease status 
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All patients will be planned to receive radical daily radiotherapy delivered in 32 or 20 fractions. Patients 
will be randomised between 3 groups;  
1. Standard Whole Bladder Radiotherapy (WBRT) (control) 
2. Standard dose Adaptive tumour focused Radiotherapy (SART) 
3. Dose escalated Adaptive tumour boost Radiotherapy (DART) 
 
In all 3 groups concomitant therapy is permitted at the local investigators discretion. 
Radiotherapy should ideally commence within 6 weeks following randomisation. However up to 10 weeks 
is permitted, to allow sufficient time for chemotherapy and/or radiotherapy planning 
Participants allocated to standard planning and delivery (control arm, group 1) will have: 
 One (1) radiotherapy plan generated to deliver all fractions on an empty bladder.   
The IGRT process is as detailed in the NRIG IGRT 2012 report for this patient group. The NRIG IGRT report 
contains detailed guidelines for IGRT practice in UK. (It is in the RAIDER trial documents on the TROG 
website for reference). 
 
Participants allocated to adaptive planning (group 2 and 3) will have: 
 Three (3) radiotherapy plans generated (small, medium and large). 
 A simultaneous integrated boost delivered at conventional dose (group 2) or dose escalation 
(group 3) to the bladder tumour in a single phase IMRT technique.  
 All fractions treated on a partially filled bladder. 
 A cone beam CT (MV or kV) taken prior to each treatment delivery to select the most appropriate 
‘plan of the day’ depending on the bladder volume size. 
 
A comprehensive QA programme will be implemented for the RAIDER trial.  This will include pre-accrual 
and during accrual components.  Selection of appropriate treatment plans for the adaptive planning group 
will be independently monitored as part of the on-going RTQA process.  
Plan selection is authorised to be carried out only by site personnel who have attained concordance with 
the gold standard for PTV selection through either RTTQA IGRT QA credentialing for UK centres and TROG 
IGRT credentialing for Australia/NZ. This is to ensure they have the advanced level skills required for the 
study. A record of QA credentialed staff should be retained in the site investigator file. 
 
This document should only be used for the management of patients in the RAIDER trial. 
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2 PLANNING CT SCAN FOR RADIOTHERAPY 
2.1 Patient preparation 
2.1.1 Group 1, 2 and 3: General Preparation 
Ideally all patients should be encouraged to empty the rectum of flatus and faeces. The routine use of 
micro enemas (e.g. relaxit) is permissible if it is standard local practice. 
Bladder preparation is dependent on patient randomisation. 
2.1.2 Group 1:  Empty Bladder 
Ensure patient has an empty bladder. Therefore all patients should be asked to void immediately before 
planning CT scan (CT0) is performed and not to drink fluids for 30minutes before the scan.  
2.1.3 Group 2 and 3:  Bladder Filling 
30 minutes prior to the planning CT scan, patients are instructed to empty their bladder and then drink 
350ml of water. Two planning scans will be acquired to inform pattern of bladder filling over time: 
 The first scan will be at 30 minutes (CT30) following drinking 
 The second scan will be at 60 minutes (CT60) following drinking.   
Voiding is not permitted between the 2 scans; however if unavoidable, the CT30 scan should be used for 
planning. 
2.2 Patient positioning 
All patients will be scanned and treated supine with arms displaced out of the radiotherapy field, using 
appropriate immobilisation techniques. 
2.3 Planning CT acquisition, scan limits and slice thickness 
Planning CT scans will be performed in the treatment position at CT slice thickness 3mm or less. It is 
recommended that the planning CT is performed without contrast, but the use of contrast is permitted if 
it is local clinical practice.  Recommended scanning levels are at least 4cm above the dome of the bladder 
to 2cm below ischial tuberosities. 
For patients treated in group 2 and 3, the planning CT scan is performed (as above) at ‘Time=30 minutes’ 
(scan 1, CT30).  A second planning CT is acquired at ‘Time= 60 minutes’ (scan 2, CT60) from end of drinking.  
The time of each scan is recorded.   
2.4 Planning CT export, fusion and evaluation of bladder filling 
The planning CT scan is exported via DICOM transfer to the treatment planning system for localization. 
For patients treated in group 2 and 3 the bladder filling must be assessed. In order to do so fuse both 
planning CT scans in the treatment planning system. CT30 will be the primary data set and CT60 will be 
the fused secondary dataset. To evaluate bladder filling, the whole bladder is localized on the CT30 and 
on the CT60 scan.   
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 If the difference in bladder filling between the 2 planning scans is less than 50ml i.e. no significant 
filling occurs all contours are to be created on CT30.   
 If difference is greater than 50mls i.e. filling occurs, the large GTV and CTV will be created on 
CT60.These shall be used to  create PTV2 and PTV for the large plan 
Please note all planning and dose calculation is to be done on CT30 (See section 4), therefore all volumes 
should be assigned to a single structure set on the CT30 scan. 
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3 LOCALISATION OF THE TARGET VOLUME AND ORGANS AT RISK 
3.1 Volume definition 
Volumes will be defined according to the International Commission on Radiation Units and Measurements 
(ICRU) report 50, supplement report ICRU 62: Prescribing, Recording and Reporting Photon Beam Therapy 
and ICRU 83: Prescribing, Recording and Reporting Photon-Beam Intensity Modulated Radiotherapy 
(IMRT). Outlining should be carried out with the aid of all diagnostic information including position of 
fiducial markers, surgical bladder map, MRI and CT scans. 
 
3.2 Gross tumour volume 
The gross tumour volume (GTV) is defined as the bladder tumour/bed. It will be delineated using position 
of fiducial markers (where available), diagnostic imaging (imaging prior to neoadjuvant chemotherapy 
where applicable) and the surgical bladder map (where available). When delineating the tumour any 
extravesical tumour should be included in GTV as should pathological bladder wall thickening unless 
clearly not due to tumour. If no tumour is visible, the appropriate section of the bladder should be 
included based on surgical bladder map +/- discussion with urologist who performed TURBT. In these 
circumstances consider repeating TURBT and placing fiducial markers adjacent to resection scar whenever 
possible. 
For patients treated in group 2 and 3, if the difference in bladder filling between CT30 and CT60 is greater 
than 50ml i.e. filling occurs, GTV is to be contoured on both scans.  
 
3.3 Clinical target volume 
The clinical target volume (CTV) is the contour encompassing the tumour/bed (GTV), the whole bladder 
and any area of extravesical spread.  The CTV should also include 1.5cm of prostatic urethra in males or 
1cm of urethra in females if tumour is at the base of bladder or if distant CIS is present. 
For patients treated in group 2 and 3, if the difference in bladder filling between CT30 and CT60 is greater 
than 50ml i.e. filling occurs, CTV is to be contoured on both scans. 
 
3.4 Organs at risk 
Organs at risk (OAR) will be outlined as solid structures by defining their outer wall. All OAR should be 
outlined on the CT0 for group 1 and CT30 only for group 2 and 3.  The following OARs should be contoured:  
 Rectum: 
The rectum is outlined to include the full circumference and rectal contents. Outlining should 
extend from the lowest level of ischial tuberosities to the recto-sigmoid junction. The recto-
sigmoid junction will be defined as the level at which there is an anterior inflection of the bowel, 
best appreciated on sagittal reconstructions on the CT planning scan. 
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 Other bowel: 
The small and large bowel (including sigmoid colon) will be outlined as a single structure. The 
entire small and large bowel visible on relevant levels of the planning scan will be outlined as 
individual bowel loops. The superior extent of outlining should be 2cm beyond the superior extent 
of PTV (group 1) and Large PTV (group 2 and 3). 
 
 Femoral heads: 
Both the femoral heads are outlined to the bottom of the curvature of their heads (femoral necks 
are not included). 
 
 
3.5 Planning target volume 
The CTV(s) will be expanded, as below, to create the PTV(s). 
For the tumour focused RT (group 2 and 3) the GTV(s) will be expanded, as below to create the PTV2s. 
 
3.5.1 Group 1: standard whole bladder RT 
For patients in group 1, receiving standard whole bladder RT, a single PTV will be created. 
1. PTV= CTV with anisotropic margin applied, as per Table 1. 
 
3.5.2 Group 2 and 3: adaptive tumour focused RT (standard dose and dose escalated) 
For patients in group 2 and 3, receiving adaptive tumour focused RT a library of 3 PTVs will be created, 




 For patients in group 2 and 3, if the difference in bladder filling between CT30 and CT60 is less 
than 50ml i.e. filling does not occur, the PTV_Sm, PTV_Med and PTV_Lar will be produced 
from the 30 minute CTV. 
 
 However, if the difference in bladder filling between CT30 and CT60 is greater than 50ml i.e. 
filling occurs, the PTV_Sm and PTV_Med will be produced from the 30 minute CTV. The 
PTV_Lar will be produced from the 60 minute CTV, as described in Table 1. 
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CTV to PTV Expansion (cm) 




CT0 PTV 0.8 1.5 1.2 1.5 0.8 





CT30 PTV_Sm 0.5 0.5 0.5 0.5 0.5 
CT30 PTV_Med 0.5 1.5 1.0 1.5 0.5 
If CT60-CT30 <50mls then 
CT30 PTV_Lar_30 0.8 2.0 1.2 2.5 0.8 
If CT60-CT30>50mls then 
CT60 PTV_Lar_60 0.5 1.5 1.0 1.5 0.5 
 
 




 For patients in group 2 and 3, if the difference in bladder filling between CT30 and CT60 is less 
than 50ml i.e. filling does not occur, the PTV2_Sm, PTV2_Med and PTV2_Lar will be produced 
from the 30 minute GTV. 
 However, if the difference in bladder filling between CT30 and CT60 is greater than 50ml i.e. filling 
occurs, the PTV2_Sm and PTV2_Med will be produced from the 30 minute GTV. The PTV2_Lar will 
be produced from the 60 minute GTV, as described in Table 2. 
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2. For Groups 1, 2 and 3 please ensure that 1.5cm of prostatic urethra in males or 1cm of urethra in 
females is included when the tumour is at the bladder base or if distant CIS is present. Please 
contact RTTQA if further guidance is required on this aspect of outlining. 
 
3. For Group 2 and 3, the CTV drawn on CT60 should not be within/smaller than the CTV drawn on 
the CT30. Thus, the CTV drawn on CT60 should encompass the CTV drawn on CT30.  This could 
occur as a result of contouring error, however it is also possible that bowel motion/filling between 
the 2 scans may also cause this (see Figures 2a-2d). In these circumstances it is advised that the 
CTV drawn on CT60 is summed to include the CTV drawn on CT30; allowing all excursions of the 
bladder to be included in the volume.  This can be done by application of Boolean operators within 
the treatment planning system used. 
 
 
Figure 2a: CT30 scan.  
 
 
Figure 2b: CT60 scan. Bladder filling occurs but is also pushed anterior due to rectal distension secondary to flatus 
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Figure 2c: Yellow contour reflects CTV on CT30. Blue contour reflects CTV on CT60. (Difference between two 
volumes >50cc). 
 
Figure 2d: Boolean operator applied to create summed CTV (purple) from which PTV_Lar_60 (and PTV2_Lar_60) 




4. The GTV should not exceed beyond the CTV outline. Where there is extra-vesical spread included 
in the GTV, the CTV must be extended outside the bladder wall to include all the GTV.  The CTV 
should be summed to include all the GTV and should share same outer-contour, see Figure 3a-3c. 
 
 The CTV_30 should encompass the GTV_30 and share the same outer contour. 
 The CTV_60 should encompass the GTV_60 (and thus the GTV_30) and should share the same 
outer contour. 
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Figure 3a: CT30 GTV (green) shares same bladder wall as CTV (red) 
 
 
Figure 3b: CT30 GTV (green) shares same bladder wall as CTV (red) 
 
 
Figure 3c: CT30 GTV (green) shares same bladder wall as CTV (red) 
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5. The GTV_60 should generally extend further superiorly and anteriorly, in comparison with the 
GTV_30, to account for expansion upon filling. 
 
6. The PTV_Lar should encompass the PTV_Med. 
 
7. The PTV2 should not exceed beyond the corresponding PTV outline. For planning purposes, the 
PTV2 should share the same outer contour as the corresponding PTV outline, i.e. it should ‘appear’ 
attached to the outer contour of the PTV. 
 
8. The clinician should indicate to the planner which CT data set (CT30 or CT60) has been used to 
create the large target volumes.  
 
9. The OTHER_BOWEL should extend to 2cm beyond the largest PTV. 
 
10. The rectum should extend to the lowest level of the ischial tuberosities. 
 




Consistent naming of contoured structures used in radiotherapy treatment planning is essential to 
facilitate the comparison of dose-volume statistics across patients for quality assurance and outcomes 
analysis. Maintaining consistency in structure names is particularly important (and challenging) in multi-
institutional clinical trials, in which treatment planning data are collected from many participating 
institutions. A scheme for uniform naming of contoured structures for RAIDER is provided in the following 




Table 3: RAIDER Trial Target Volume and OAR Nomenclature 
Structure Name Description 
GTV_0 Contouring the primary bladder tumour for patients 
randomised to Group 1 (WBRT) is not required for trial 
purposes. Local standard practice should be followed if 
contouring GTV aids subsequent CTV delineation (on CT_0)  
GTV_30 Primary bladder tumour contoured on CT30 for group 2 and 
3 
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GTV_60 Primary bladder tumour contoured on CT60 for group 2 and 
3 if the difference in bladder filling between CT30 and CT60 
is greater than 50ml  
CTV_0 GTV + whole bladder + extravesical spread (+ 1.5cm of 
prostatic urethra in males or 1cm of urethra in females if 
tumour is at the base of bladder or if distant CIS is present) 
contoured on CT0 for group 1 
CTV_30 GTV + whole bladder + extravesical spread (+ 1.5cm of 
prostatic urethra in males or 1cm of urethra in females if 
tumour is at the base of bladder or if distant CIS is present) 
contoured on CT30 for group 2 and 3 
CTV_60 GTV + whole bladder + extravesical spread (+ 1.5cm of 
prostatic urethra in males or 1cm of urethra in females if 
tumour is at the base of bladder or if distant CIS is present) 
contoured on CT60 for group 2 and 3 
PTV_Std CTV_0 + anisotropic margin (see table 1)  
For Standard Whole Bladder-group 1 only 
PTV_Sm CTV_30 + margin 
PTV_Med CTV _30 + margins  
PTV_Lar_30 CTV_30 +margins, when no filling occurs between CT30 and 
CT60) 
PTV_Lar_60 CTV_60 +margins, when filling occurs between CT30 and 
CT60) 
PTV2_Sm GTV_30 + margin 
PTV2_Med GTV_30 +margins  
PTV2_Lar_30 GTV_30 + margins, when no filling occurs between CT30 and 
CT60) 
PTV2_Lar_60 GTV_60 + 0.5 – 1.5cm margins, when filling occurs between 
CT30 and CT60) 
PTV_Sm-PTV2_Sm PTV_Sm minus PTV2_Sm 
PTV_Med-PTV2_Med PTV_Med minus PTV2_Med 
PTV_Lar-PTV2_Lar PTV_Lar minus PTV2_Lar 
RECTUM Rectum 
OTHER_BOWEL Small and large bowel (including sigmoid colon) 
FEMORALJOINT_L (UK) FemJoint_L 
(Aus) 
Left femoral head (ball only) 
FEMORALJOINT_R 
(UK)FemJoint_R (Aus) 
Right femoral head (ball only) 
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It is mandatory for all RAIDER patients to be CT planned. In general, the method of treatment planning 
will vary from site to site and should be specified in each centre’s process document. 
For group 1 the use of three or four 3D conformal radiotherapy (3DCRT) fields, five to seven static fields 
intensity modulated radiotherapy (IMRT) or volumetric modulated radiotherapy (VMAT) treatments (e.g. 
RapidARC, VMAT, Tomotherapy) are acceptable. Please inform the relevant QA group and the CTU if a 
group 1 patient requires re-planning (or re-scanning) during treatment. 
For group 2 and 3 the aim of the plan is to do partial bladder sparing while maintaining the PTV 
prescription dose, use of 5-7 static fields IMRT (5 fields are preferred due to shorter treatment time) or 
VMAT is recommended. The use of forward planned simple IMRT (‘field in field’) or tomotherapy are also 
acceptable alternatives. The same technique should be used for all patients randomised to group 2 and 3. 
All plan and dose calculation is to be done on CT30 irrespective of filling. 
Please inform the relevant QA group and the CTU if a group 2 or 3 patient requires re-planning (or re-
scanning) during treatment. 
The local investigator should ensure appropriate quality assurance methodologies are in place for the 
chosen planning technique.  
 
4.1 Standard Planning 
For patients randomised to group 1 standard planning a single plan will be created.   
 Plan_Std = PTV_Std 
 
4.2 Adaptive Tumour Focused Planning 
For those randomised to adaptive planning a series of 3 plans will be created using the PTV Small, PTV 
Medium and PTV Large and the corresponding PTV2.  The isocentre for all 3 plans must be identical. 
 Plan_Sm = PTV_Sm& PTV2_Sm 
 Plan_Med = PTV_Med& PTV2_Med 
 Plan_Lar = PTV_Lar_30 and PTV2_Lar_30 or PTV_Lar_60 and PTV2_Lar_60, depending 
on filling. 
For IMRT planning centres may prescribe plan to either a mean or median dose to PTV2, depending on 
their normal practice, as it is anticipated in an optimised plan the difference between these two 
parameters will be minimal. For 3D-CRT the prescription should be 100% at the ICRU reference point. 
 
The prescription doses for RAIDER patients are detailed in Table 4. 
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64 32 2 55 20 2.75 
PTV 
(PTV – PTV2) 










70 32 2.1875 60 20 3 
 
PTV 
(PTV – PTV2) 
52 32 1.625 46 20 2.3 
 
 
4.3 Target volume dose objectives 
Three dimensional dose distributions should be produced. The dose distribution should be assessed for 
coverage of the PTV and normal tissues using appropriate transverse sagittal and coronal views. The 
following optimal and mandatory target volume dose constraints are proposed: 
 
Table 5: Target dose objectives 
Volume Dose Constraints Optimal Mandatory 
PTV2 
 
D98% ≥95% of prescribed dose ≥90% of prescribed dose 
*D50% - +/- 1% of prescribed dose 
D2% ≤105% of prescribed dose ≤107% of prescribed dose 
PTV 
(PTV – PTV2) 
D98% ≥95% of prescribed dose ≥90% of prescribed dose 
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*Please note that D50% constraint refers only to PTV2.  PTV D50% is likely to be exceeded depending on 
size of PTV2. Therefore no compromise to PTV2 coverage should be made at the expense of achieving D50% 
PTV constraint. 
 
4.4 Normal tissue dose constraints 
The dose to OAR should be minimised. The following dose volume constraints are a guide.  
Ideally, for Groups 2 & 3 optimal constraints for other bowel should be met for Plan 1 (small) and 
mandatory constraints for other bowel should be met for Plan 2 (medium). Provided the Plan 3 (large) has 
been adequately optimised it is recognised that some of the rectum and other bowel mandatory 
constraints may not be achieved.  
Likewise for group 1 patients, provided the plan has been suitably optimised, some rectum and other 
bowel dose tolerances may be exceeded due to inclusion within the PTV. It is at the local Principal 
Investigator’s discretion to accept the OAR doses and should be noted on the plan assessment form. The 
DVH assessment for each plan should be with the overall prescribed dose. 
For patients in group 3, if mandatory dose constraints are not met on the medium plan advice must be 
sought from the RAIDER QA team.   
For this reason it is recommended for adaptive planning the medium plan is produced first, this should 
then be copied and the relevant objectives and prescription volume are changed for the small and large 
plans.   Dose to the PTV2 or PTV must not be compromised in order to meet the normal tissue 
constraints.   
 



















































40% only in Group 3 (DART) 
Otherwise 0% in Group 2 (SART) 
Mandatory 
80% 
50% only in Group 3 (DART) 
Otherwise 5% in Group 2 (SART) 
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Body-PTV (Normal 
Tissue) D1cc ≤105% of prescribed dose ≤110% of prescribed dose 
 
**Whole bladder (CTV) constraint specified above (Table 6a) should be used to inform plan optimisation. 
Please contact the RAIDER QA team if you fail to meet this constraint.  
Bladder outside PTV2 (i.e. CTV-PTV2) meeting V60Gy and V65Gy absolute constraint of 80% and 50% 
respectively will be collected for reporting of primary endpoint. 
 
Table 6b: OAR Dose constraints for 20-fraction schedule 
 
***Whole bladder (CTV) constraint specified above (Table 6b) should be used to inform plan 
optimisation. Please contact the RAIDER QA team if you fail to meet this constraint. 
Bladder outside PTV2 (i.e. CTV-PTV2) meeting V50Gy and V54.2Gy absolute constraint of 80% and 50% 
respectively will be collected for reporting of primary endpoint. 
 
Normal tissue dose constraints and dose volume histograms (DVH) for 20 fraction schedule are presented 
in Table 6b (recalculated from above using linear quadratic equation, assuming that all α/β of organs at 



















































40% only in Group 3 (DART) 
Otherwise 0% in Group 2 (SART) 
Mandatory 
80% 
50% only in Group 3 (DART) 




D1cc ≤105% of prescribed dose ≤110% of prescribed dose 
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4.5 Planning recommendations 
 Produce the medium plan first. 
 
 For the planning priorities should be as follows, in order of importance: 
1. Achieve 95% coverage of PTV2 
2. Achieve 95% coverage of the PTV 
3. Achieve mandatory OAR dose constraints 
4. Achieve optimal OAR dose constraints 
5. Reduce areas of high dose within PTV-PTV2 especially away from boost site 
Therefore, for the majority of cases dose coverage of the PTV_2 and PTV volumes should not be 
compromised to reduce dose to OAR without first contacting RTTQA for advice. 
 For Group 2 & 3, review all three plans together after planning using the plan comparison 
function. The dose to the RECTUM and OTHER_BOWEL should stay the same or get progressively 
higher as the PTV size gets larger i.e. the dose statistics should not be better for the large plan 
than the small or medium plan. 
 If throughout the course of treatment any patient requires re-planning please contact the relevant 
QA group. 
 If the PTV volume is outside the patient’s body please contact the relevant QA group. 
 
4.6 Pre-Treatment checks 
To minimise risk of error at the time of importing, exporting and plan selection, please ensure that each 
beam name and ID reflects the assigned plan i.e. Sm_Plan. 
At the time of plan exporting, it is recommended to find a way of ensuring that centres’ local record and 
verify systems cannot mix beams from different plans. For example create each plan with slightly different 
contributions from each field so that only the correct combination of beams can be chosen on any given 
day (Applicable only to Mosaiq). This could be done by adding 2 points diagonally on the isocentre slice 
with a dose close to the 100% isodose. Then all beams can be assigned from a plan to each of the points 
as the reference point.  
Please ensure that the safe scheduling of multiple treatment fields and recording the dose delivered is 
considered for RAIDER patients. Additionally, please ensure that the safe scheduling of imaging only fields 
is considered. These procedures will be captured in the process document. If you have any questions 
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5 TREATMENT DELIVERY 
It is important to ensure that patients follow the bladder preparation instruction for their group as they 
have done at the planning CT scan appointment (i.e. empty for group 1 and partially full for group 2 and 
3).   
5.1 Standard whole bladder RT (group 1) 
Acquire pre-treatment cone beam CT images using a full pelvis scan. Image match and register bone, 
according to the recommendations stated in the NRIG IGRT report.  
Make required corrections/shifts as per departmental practice. 
The acquired cone beam CT image can be used for assessment of target coverage at the individual 
department’s discretion.  Such use will be documented. Any changes made on the basis of the scan should 
be reported in the CRF and to RTTQA (including exposures not resulting in treatment because of patient 
factors).  
Schedule imaging for Group 1 patients, as per departmental protocol. In addition to this please ensure a 
post-treatment CBCT is taken in the first week and weekly for these patients. 
 
 
5.2 Adaptive Tumour Focused RT (SART and DART) 
Acquire pre-treatment cone beam CT image and register bone according to the recommendations stated 
in the NRIG IGRT report. Make any corrections according to departmental practice. 
An appropriately RTTQA trained and accredited healthcare professional should review the bone matched 
CBCT, to assess bladder filling and PTV coverage. The following steps should assist centres when assessing 
the CBCTs. 
The aim in treating adaptive patients is to use the smallest plan possible, so that the dose is minimised to 
the OARs without compromising both PTV and PTV2 coverage.   
The steps below describe how this can be best achieved at plan selection. It is important to review overall 
bladder filling, and PTV2 boost position as determined on the planning CT scans before plan selection.   
 
5.2.1 Image Match and Plan Selection Steps: 
1. Following CBCT, the bladder filling and size should be checked against CTV_30 contour.   
2. If the bladder is of similar shape and size to the CTV at planning (i.e. CTV_30), then the small plan 
should be preferably considered in the first instance for treatment.  
3. Once the bladder filling and shape has been assessed begin to review the appropriate PTVs. An 
appropriate plan provides suitable coverage of the PTV2 and PTV, with minimal normal tissue 
irradiation. 
4. Manual (soft tissue) moves should be made to ensure the bladder is adequately covered whilst 
selecting the smallest plan possible to spare normal tissue. Please be mindful of the magnitude 
of the soft-tissue shift, moves greater than 1cm can impact on the accuracy of the expected 
dosimetry. Discuss with planning department if  this shifts over 1cm occur and contact RTTQA 
retrospectively. 
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5. Additional manual moves can be undertaken if felt it could further optimise PTV2 coverage.  
Manual moves prioritising coverage to the boost region over the normal bladder wall is permitted 
if it avoids excessive normal tissue irradiation that would have occurred by selecting a larger plan.  
Again, please be mindful of the magnitude of the soft-tissue shift, moves greater than 1cm can 
impact on the accuracy of the expected dosimetry. Discuss with planning department if  this shifts 
over 1cm occur and contact RTTQA retrospectively. 
6. Assess the OAR. Review if they are similar to planning scan. Additionally it is important to check 
where they are relative to PTV2 i.e. ensuring not in PTV2, especially for DART patients. 
The actions taken for each patient must be confirmed by a second appropriately trained and accredited 
healthcare professional. Once agreement has been reached any correction should be performed and the 
plan selection agreed and confirmed for treatment. 
5.2.2 Image Match and Plan Selection Tips: 
This guidance is provided  to assist RAIDER trained staff with potential solutions for  scenarios that may 
arise on treatment.   Further guidance is provided in APPENDIX E.  Fractions must not be omitted or missed 
due to unfavourable positioning of normal anatomy  such as rectal distention due to flatus or faeces.   
 Please only choose a large plan if the bladder has filled. (E.g. If the bladder has filled more than 
the CTV_30, and the patient has a CTV_60, overlay the CTV_60 to assess the magnitude of the 
filling). 
 Please consider the nature of bladder filling. We would expect filling to occur in the anterior and 
superior direction. 
 Please be mindful of minimising image match and plan selection time. 
 If the bladder is significantly smaller than the CTV 30 contour at planning, it is likely that the PTV2 
boost is in the incorrect position and, or does not achieve adequate normal bladder sparing.   In 
these circumstances patient should not proceed but be removed from the couch, and encouraged 
to fill the bladder by drinking further, and/or increasing the time interval of image acquisition.  
The local PI and RTTQA/TROG should be informed. 
 In the event that the bladder has over filled and none of the library PTVs cover the entire bladder 
despite manual move the patient should be asked to minimally void and the CBCT is repeated. If 
this is not possible, patient should void completely and restart drinking protocol but consider 
reducing the time interval for CBCT acquisition (see appendix C and D).  In these circumstances a 
member of the clinical team should also be notified to ensure the patient is not in urinary 
retention. If the large plan is being regularly selected, during a single treatment week, please 
contact the RTTQA/TROG to discuss this patient. 
 Caution should be taken when changing the drinking protocol. Please consider changing one 
aspect of the protocol at a time, i.e. change the timing only or change the amount of water only. 
 If no contours are suitable because of rectal gas, then remove the patient from the bed and ask 
them to void. Repeat the above steps. If contours still not suitable select the most suitable plan, 
i.e. optimising coverage to PTV2 and minimising the inclusion of Oars. If this occurs repeatedly 
(e.g. more than twice in 5 fractions) please contact RTTQA for advice.    
 All CBCT exposures including those not resulting in treatment should therefore be recorded on 
the CRF and plan selection form. 
 The patient’s hydration may be different on chemotherapy days. Care should be taken when 
adjusting the drinking protocol on these fractions. 
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 Please review the post-treatment CBCTs to ensure the patient’s bladder has not filled beyond the 
plan selected.  If this has occurred, then consider the length of time taken for plan selection and 
see section 5.3.    
 
5.3 Post treatment 
A post treatment cone beam CT should be taken in the first week and once a week thereafter (for all 
randomised groups, including group 1). It should be reviewed locally to ensure intra fraction filling has 
been accommodated in plan selection. Please discuss with the PI and contact RTTQA if there are any issues 
with intra-fraction filling. 
 
5.4 On completion of radiotherapy 
On completion of radiotherapy planning, all plans including CT images, structures, plan and dose matrix 
and plan assessment form (PAF), should be exported, anonymised and sent to the RTTQA or TROG team 
electronically following the exporting data guidelines in the QA appendix A&B. On completion of a 
patient’s treatment, the plan selection form, first week and then weekly paired (pre and post 
radiotherapy) CBCT scans and the registration objects (Aria only) should be sent to the RTTQA or TROG 
team. Investigators should notify the QA team before deleting any relevant data. 
Please ensure that all patient data is anonymised prior to sending it to RTTQA/TROG. If you have any 
difficulties anonymising the data, please contact RTTQA/TROG.  
 
Sending data from Elekta/Mosaiq systems: 
Week 1 and weekly pre and post treatment CBCT data should be exported from the XVI using “Option 3”. 
This ensures the CBCT data is sent to the QA team in the correct treatment position. 
Sending data from Varian/Aria systems: 
Week 1 and weekly pre and post treatment CBCT data should be exported from Aria along with the online 
registration object.  This ensures that the CBCT data can be reviewed in the treatment position by the QA 
team. Please refer to guidance in Appendix G& H. 
 
6 TREATMENT SCHEDULING AND GAPS 
Treatment interuptions during radiotherapy should be avoided as they have detrimental effect on 
outcome.  Treatment must not be interrupted due to staffing issues.   Advice should be sought from the 
RTTQA team and ICR-CTSU in real time if issues with patient scheduling and gaps arise.   
 
If IGRT is unavailable due to unpredicted staff changes, machine breakdown and/or gap day treatment, 
patients in group 2 and 3 may be treated for up to 5 days using the PTV medium plan without plan 
selection. Pre-treatment CBCT where possible should still be acquired.. These pre-treatment CBCTs should 
be sent to RTTQA for review in addition to the CBCTs which are routinely collected. 
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In the event of machine service, breakdown, or bank holiday, compensation for the missed fraction should 
be made.  In the first instance the local PI should advise on how this should be made, but it is expected to 
be achieved by either treating at a weekend or undertaking two fractions a day (ideally on a Friday with a 
minimum 6 hour gap between treatments). If the treatment machine is unavailable for more than 3 days, 
please contact the ICR-CTSU and QA team. 
Should a treatment break occur  due to toxicity, sites are advised to contact ICR-CTSU and/or RTTQA in 
real time. Compensation is not expected in these circumstance.  
All missed fractions are to be reported to the ICR-CTSU and QA team.   
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APPENDIX A: 




The UK quality assurance programme for RAIDER comprises the following exercises detailed 
below: 
Pre-Trial Quality Assurance 
1. Facility questionnaire: This is designed to gauge the IGRT experience of a centre to 
date. It collects information regarding the type of IGRT used, action thresholds, 
frequency of interventions and imaging doses. This survey should be accessed online 
via: http://www.rttrialsqa.org.uk/rttqa/ 
 
2. Process document: Details are collected on all aspects of tasks for the complete 
patient pathway and includes details on all imaging procedures. A process document 
template can be found at http://www.rttrialsqa.org.uk/rttqa/ 
 
3. Outlining Benchmark cases:  One case with lipiodol and one case without lipiodol will 
be provided by the RTTQA to be completed by the P.I for each recruiting site. The 
targets and organs at risk are to be named and delineated as per the RAIDER 
radiotherapy planning and delivery guidelines. Those sites that have successfully 
completed the outlining for another related NIHR trial will not be required to outline 
the organs at risk, only the target volumes.  Please contact the QA team to confirm. 
 
4. Planning Benchmark case: One planning benchmark case provided by RTTQA is to be 
planned according to the Group 3 randomisation arm.  
 
5. In house IGRT training programme: It is a requirement of RAIDER that sites have an 
established IGRT training programme already in place before joining the trial. Sites 
should be utilising cone beam CT for treatment of bladder patients.  
 
6. Bladder ‘Plan of the Day’ training: Two practice cases with 6 CBCTS each are provided 
for centres to work through with an accompanying training document.  Case 1 
includes answers with some step-by-step instructions, for case 2 the answers only are 
Contact for scientific queries 
Dr Shaista Hafeez 
Tel:  Tel: 0208 661 3274 
Email:  Shaista.Hafeez@icr.ac.uk 




Amanda Webster RTTQA Group 
Tel: 0203 826 2320 
Email:  
raiderqa.enh-tr@nhs.net 
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provided. The cases can be provided on an Elekta or Varian database depending on 
which system is used by a site. Please contact RTTQA for the training guidance 
document. Those that have successfully completed the ‘Plan of the Day’ training for 
HYBRID do not need to complete this again. 
 
7. RAIDER ‘Plan of the Day’ training video will be available for streaming on the RAIDER 
ICR website. Please contact RTTQA or ICR for access  
 
8. RAIDER Plan of the Day assessment: Centres will be given details of two patients with 
6 CBCTs each (12 match decisions) to allow individuals to make plan of the day 
decisions/choices. The match results will be exported to the RTTQA group for review. 
Those staff members that have completed the ‘Plan of the Day’ assessment for Hybrid 
will not be required to complete the assessment. All QA approved individuals will 
receive a confirmation of their RAIDER accreditation to undertake plan of the day 
assessments for RAIDER patients.   
 
9. Verification of electronic data transfer: Check DICOM or RTOG data can be suitably 
anonymised and transferred to and from centres. This includes the planning data and 
on treatment data, i.e. CBCT and registration objects. 
 
 
On-Trial Quality Assurance 
 
 
1. Prospective plan review: The outlining and planning for at least the first adaptive 
patient and the first dose escalated patient (if the first patient is not dose escalated) 
will be subject to prospective review by the RTTQA group. 
 
2. Ongoing data collection: All planning data (CT,RS, RD, RP files, PAF) and treatment 
delivery data (weekly pre and post treatment CBCT and registration objects (if 
available) will be collected by the RTTQA group for retrospective review 
 
3. IGRT/POD selection support: The first adaptive patient randomised by all sites will be 
subject to a retrospective review. If centres have any difficulties in the plan selection, 
please do not hesitate to contact RTTQA. 
 
Data Export 
Please contact raiderqa.enh-tr@nhs.net for information on data transfer.  
Please ensure that data is appropriately labelled when sent to RTTQA, i.e. trial name, 
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For all patients please ensure the following data is sent for all RAIDER patients: 
 
Table 7: 
RAIDER Data Checklist Sent 
Diagnostic Information (e.g. report, screenshot of imaging)  
ALL planning CTs (e.g. include CT_30 and CT_60 for adaptive 
patients) 
 
Structure set, Dose Cube, Plan  
Plan Assessment Form  
Plan Selection Form (For all trial patients)  
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APPENDIX B: 
Trans Tasman Radiation Oncology Group: Australia & NZ 






1. Facility questionnaire: This is designed to gauge the IGRT experience of a centre to date. 
It collects information regarding the type of IGRT used, action thresholds, frequency of 
interventions and imaging doses.  For simpler completion at centres, TROG have created 
two sections, one for Radiation Therapists and another section for Radiation Oncology 
Medical Physicists, which may be completed separately.  This questionnaire can be 
accessed online at: www.trog.com.au. In addition, sites wishing to use inversely planned 
techniques must be credentialed to do so. Please contact qa@trog.com.au for further 
information.  
 
2. Process document: Details are collected on all aspects of tasks for the complete patient 
pathway and includes details on all imaging procedures. A process document template 
can be found at http://www.trog.com.au/Trials-and-research-projects, RAIDER, Quality 
Assurance. TROG website password required. 
 
3. Fiducial Marker Quality Assurance Document: To be completed by sites who have 
indicated that they intend to use fiducial markers. This document can be found at 
http://www.trog.com.au/Trials-and-research-projects, RAIDER, Quality Assurance. TROG 
website password required. 
 
4. Outlining Benchmark cases: The P.I. from each recruiting site should complete the two 
outlining benchmarking cases available on the TROG website. One male (with lipiodol and 
one female (without lipiodol). The targets and organs at risk are to be named and 
delineated as per the RAIDER Radiotherapy Planning, Delivery and QA Guidelines.  
 
Male Case 1:  Download TROG 14.02 BMKXX1 from http://www.trog.com.au/Trials-and-
research-projects, RAIDER, Quality Assurance.  TROG website password required. 
Primary ANZ sponsor contact 
details 
Trans Tasman Radiation Oncology Group 
Contact for public queries 
Patrick Wheeler 
+61 2 4014 3903 
RAIDER@trog.com.au 
Contact for scientific queries 
Prof Farshad Foroudi 
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Female Case 2:  Download TROG 14.02 BMKXX2 from http://www.trog.com.au/Trials-
and-research-projects, RAIDER, Quality Assurance. TROG website password required. 
 
Once the outlining cases have been completed by the local P.I. an export of the CT images 
and structure sets in DICOM should be returned to the TROG QA team. All data must be 
transferred via Central Quality Management System (CQMS). CQMS can be accessed 
through https://cqms.trog.com.au/login.jsp. If you require a CQMS account, please 
contact qa@trog.com.au 
 
5. Planning Benchmark case: One planning benchmark is to be planned according to the 
Group 3 randomisation arm of the trial.  
 
Download TROG 14.02 BMKXX3 from http://www.trog.com.au/Trials-and-research-
projects, RAIDER, Quality Assurance.  TROG website password required. 
 
Once the planning benchmark case (with three plans) has been created (with appropriate 
review and acceptance by the local P.I.) the export of the CT images, dose matrices, RT 
plan and structure sets in DICOM should be returned to the TROG QA team. All data must 
be transferred via the Central Quality Management System (CQMS). CQMS can be 
accessed through https://cqms.trog.com.au/login.jsp. If you require a CQMS account, 
please contact qa@trog.com.au. 
 
6. In house IGRT training programme: It is a requirement of the RAIDER trial that sites have 
an established IGRT training programme already in place before joining the trial. Sites 
should be utilising cone beam CT for treatment of bladder patients. Successful 
participation in the TROG 10.01 BOLART trial including the e-learning will be regarded as 
satisfying these criteria. IGRT training programme details are requested as part of the 
Facility Questionnaire. 
 
7. IGRT Credentialing: 
a. Bladder ‘Plan of the Day’ training: Two practice cases with six CBCTS each are 
provided for centres to work through with an accompanying training document.  
Case 1 includes answers with some step-by-step instructions, for case 2 the answers 
only are provided. The cases are provided in DICOM format via the TROG website. 
Sites must import the two cases with accompanying CBCTS into appropriate image 
matching/registration software. The training guidance document is accessible via 
the TROG website.  
 
b. Bladder ‘Plan of the Day’ training video: Available on the TROG website: 
www.trog.com.au 
 
c. RAIDER Plan of the Day assessment: Two patients with six CBCTs each (twelve 
match decisions) will be provided to sites to allow individuals to make plan of the 
day decisions/choices. Staff must record their match results using the Plan of the 
Day Assessment Form. Assessment forms must be submitted to qa@trog.com.au. 
 
8. Dosimetry Audit: All sites who have participated in the TROG 10.01 BOLART trial will not 
be required to complete a dosimetry phantom study. For sites who have not participated 
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Please contact TROG QA for advice as required for the first patient planning and treatment.  
Teleconference facilities may be made available if required. 
 
1. Quality assurance Pre-treatment Plan Review: Pre-treatment review of at least the first 
adaptive patient and the first dose escalated patient (if the first patient is not dose 
escalated) recruited from each site will be conducted by TROG. The first participant with 
fiducial marker placement from each must also be submitted for review.  
 
The treatment plan will be required for review at least one week prior to treatment 
commencement. If the review results are acceptable the participant will proceed to 
treatment.  
 
The following four adaptive patients from each site will undergo timely review (to be 
completed during the first week of treatment).  
 
A checklist of the source data required for each RT QA case will be provided by the TROG 
QA Office with specifications of timelines for data submission included. See below for 
instructions for the upload of source data required for real time pre-treatment 
radiotherapy QA.  
 
2. Quality assurance Post-treatment Plan Review: Adaptive patients will be sampled for QA 
review at a rate of one in five for post-treatment review following the initial pre-
treatment/timely sampling.   
 
Patients in the standard whole bladder radiotherapy arm will be sampled for QA review 
at a rate of one in five for post-treatment review. 
 
All participants will be required to submit data at the end of treatment. This data should 
be submitted via CQMS. To assist with this process a checklist of the source data required 
will be provided to you by TROG QA. Timelines for data submission will also be specified. 
 
3. IGRT/POD selection support: The first adaptive patient randomised by all sites will be 
subject to a retrospective review. If centres have any difficulties in the plan selection, 
please do not hesitate to contact the TROG QA team. 
 
Data Export and Upload 
 
Australia and New Zealand sites uploading data to TROG CQMS are not required to anonymise 
data prior to upload. All DICOM files are automatically de-identified at the point of upload to 
CQMS.  
 
Radiation Therapy Treatment Plan 
An electronic export of the radiotherapy treatment planning data file from the treatment 
planning system is required in DICOM-RT format. Please submit the RT Treatment Plan Export 
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[CT files, structure set, RT plan and dose matrix for each PTV] using the [RT Plan Upload] 
function listed in CQMS. Exported files must be uploaded as a single zipped file into CQMS.  
 Please include ALL planning CTs (e.g. include CT_30 and CT_60 for adaptive patients) 
 
CBCT Data Upload 
The following files are also to be uploaded using the [RT Plan Upload] function listed in CQMS 
for final end of RT QA review:  
 All pre and post treatment CBCT (exported in DICOM format). Each CBCT dataset 
should be uploaded as a single zipped file. As a minimum for all groups, this should 
include week 1 and weekly post-treatment CBCTs. 
 Registration objects 
 Please refer to Appendix G, H and I for additional assistance when exporting CBCT 
datasets from ARIA, MOSAIQ and Raystation 
 
Supplementary Information Data Upload 
The following files are to be uploaded using the [Other Upload] function listed in CQMS for 
final end of RT QA review:  
 Treatment prescription (including total dose, number of fractions, dose per fraction, 
prescription isodose)  
 Treatment plan summary (including field information and beam parameters)  
 Plan of the day decisions (Plan Selection Form) 
 Verification images demonstrating correct export of the radiotherapy plan (JPEG of 
the DVH and isodose distribution). 
 Daily Dose Record (including dates of treatment delivery)  
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QA Benchmark Cases: Outlining and Planning 
 
PRE-TRIAL OUTLINING BENCHMARK CASE 
All centres wishing to participate in the RAIDER trial will need to complete the following 
contouring exercise. DICOM CT data sets can be downloaded from the RTTQA website 
(www.rttrialsqa.org.uk) or TROG website (www.trog.com.au). See QA Appendix A& B for more 
information. 
Outlining Benchmark Case 1: T2N0M0 Male Pelvis 
History: 72 year old male, presented with haematuria.   Proceeded with TURBT and 3 cycles 
neo-adjuvant chemotherapy (cisplatin-gemcitabine).  Post treatment cystoscopy shows 
pathological complete response (pCR).  Patient is planned for chemo-radiotherapy to bladder.  
Biopsy: biopsy at diagnosis consistent with pT2a G3 TCC with no associated distant CIS 
Initial staging diagnostic information: Information available for contouring/GTV delineation 
includes: 
 bladder map/cystoscopy showing tumour present left lateral wall around left ureteric 
orifice 
 CT baseline (pre-chemotherapy) 
 MRI baseline (pre-chemotherapy) and lipiodol injected at tumour / scar (post 
chemotherapy) 
Radiotherapy contouring/planning (according to group 2 and 3): Planning scan at 30 minutes 
and 60 minutes reflect no filling (<50cc). 
Contouring Instructions: 
Please import Case 1 into your TPS. 






 FEMORALJOINT_L or FemJoint_L 
 FEMORALJOINT_R or Femjoint_R 
 
Please create the following PTV volumes using the expansion information contained 
in Table 1 and Table 2: 
 PTV_Sm 
 PTV_Med  
 PTV_Lar_30  
 PTV2_Sm 
 PTV2_Med 
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NB: Please refer to the additional diagnostic information available for this patient. 
 
Additional Diagnostic Information for Outlining Benchmark Case 1 






Cystoscopy, bladder biopsy and lipiodol injection 
Lithotomy, WHO checklist, pressure points protected, gentamicin. 
Bimanual no pelvic mass, smooth prostate 
Excellent views with 21 Fr scope and 12° lens. No visible tumour in bladder. Scar above left 
ureteric orifice - biopsied and lipiodol injected submucosally. New red patch at dome seen–
region biopsied and lipiodol injected. Additional three random biopsies taken. 
  
Histopathology: 
Fibrosis only at all biopsied sites.  Therefore red patch at bladder dome although injected with 
lipiodol should not to be included in GTV volume) 
  
 
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Outlining Benchmark Case 2: T2N0M0 Female Pelvis 
History: 66 year old female presented to urologist with isolated episode of frank haematuria.    
Proceeded to TURBT.  She started neo-adjuvant chemotherapy (cisplatin-gemcitabine) but 
suffered deterioration in hearing so went on to have chemo-radiotherapy to bladder after 1 
cycle.  
Biopsy: G3 pT2 TCC bladder with focal adjacent CIS 
Initial staging diagnostic information: Information available for contouring/GTV delineation 
bladder map/cystoscopy tumour present left posterior wall ureteric orifice, CT baseline (pre-
chemotherapy), MRI baseline (pre-chemotherapy, post TURBT) - non-contributory. 
Radiotherapy contouring/planning (according to group 2 and 3): Planning scan at 30 min and 
60 min reflect filling (>50cc).  
Contouring Instructions: 
Please import Case 2 into your TPS. 
 







 FEMORALJOINT_L or FemJoint_L 
 FEMORALJOINT_R or FemJoint_R 
 
Please create the following PTV volumes using the expansion information contained 
in Table 1 and Table 2: 
 PTV_Sm 
 PTV_Med  





Once the outlining benchmark cases have been created, reviewed and accepted by 
the local PI, the export of the CT images and structure sets in DICOM should be 
returned to the appropriate QA team. See QA appendix A & B for information on data 
export. 
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PRE-TRIAL PLANNING BENCHMARK CASE 
All trial centres must complete and submit the RAIDER pre-trial planning benchmark case. The 
CT DICOM data and pre-outlined structure set is available for download from 
www.rttrialsqa.org.uk (UK) or www.trog.com.au (Australia/NZ). Details for the planning cases 
are given in the next section. 
Benchmark Planning Case: T2N0M0 TCC male pelvis 
History: 63 year old male presented with frank haematuria, proceeded to TURBT; unsuitable 
for neo-adjuvant chemotherapy in view of co-morbidities, received chemo-radiotherapy to 
bladder 
Biopsy: G3 pT2a TCC bladder 
Initial staging diagnostic information: Information available for contouring/GTV delineation 
includes: 
 Radiotherapy Bladder map/cystoscopy tumour present right bladder wall 
 CT baseline,  
 MRI baseline (post TURBT non-contributory).  
Radiotherapy contouring/planning (according to group 3): Planning scan at 30 min and 60 
min; filling (>50cc). PTV small/medium contours on 30minute scan; PTV Large created on 
60minute scan 
Planning Exercise: 
Please import the CT and structure sets into your own TPS system. Following the RAIDER trial 
protocol and radiotherapy planning and delivery guidelines please produce a series of three 
radiotherapy plans as the patient is randomised to the dose escalated adaptive tumour boost 
DART (group 3) 
Structures: 
The CT has been delineated by a trial clinician with the following structures: 
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Please DO NOT edit any of these structures. The names and volumes on which the structures 
appear on have been given so that you can check that the structures have been imported 
properly. 
Data Export 
Once the planning benchmark case (three plans) has been created and reviewed and 
accepted by the local PI, the export of the Plan Assessment Form (PAF), CT images, 
dose matrices, RTplan and structure sets in DICOM should be returned to the RTTQA 
team (UK) or TROG team (Australia/NZ). For information on data export see QA 
appendix A & B. 
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Quick Contouring Checklist Adaptive Arms 
 
 
1) Outline CTV_30 on CT30. Check whether appropriate for urethra to be included. 
2) Copy and paste CTV_30 onto CT60. Rename CTV_60.  Edit this volume to take into 
consideration bladder filling taking care not to make the volume smaller inferiorly. 
3) Check CTV_30 does not expand beyond CTV_60. Use Boolean functions can be used 
to ensure CTV_60 always encompasses CTV_30. 
4) Check volume difference between CTV_30 and CTV_60. If less than 50cc, expand all 
PTV volumes from target volumes on CT30, if greater than 50cc create large PTVs from 
CT60 target volumes. 
5) Outline GTV_30 (and GTV_60 if applicable) 
6) Ensure GTV shares the same bladder wall as CTV by either manual editing and/or use 
of Boolean operators. 
7) Create adaptive PTVs from CTV using the relevant expansions 
8) Create adaptive PTV2s from GTV using the relevant expansions 
9) Check PTV_Lar encompasses PTV_Med and PTV_Sml 
10) All OARs are always outlined on CT30 (FEMORALJOINT_L, FEMORALJOINT_R, RECTUM 
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Proposed patient intervention to be considered in circumstances 





*If no plan provides appropriate coverage (bladder persistently too big or too small) more 
than twice in 5 fractions despite intervention, it is advised that the RTQA team is contacted 
for advice as in rare circumstances replan maybe indicated. 
If the bladder is too small sites can consider treating with the small plan OR removing the 
patient from the treatment couch to allow for more filling. 
**When considering changing the drinking protocol, only consider 1 timing or drinking change 
at a time. This will allow centres to establish which intervention has an effect on the patient’s 
bladder.  
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APPENDIX F 
RAIDER training cases and examples 
 









Reference image  
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2. Bladder too small.  
Bladder appears significantly under filled compared reference image, most apparent 
on sagittal localisation view.  Note boost dose includes large proportion of bladder.  
Acceptable for treatment with chosen plan as no compromise to bladder coverage.  
Patient review is recommended prior to next fraction to assess drinking protocol and, 
or time to image acquisition in order to optimise normal tissue sparing.  
Reference image 
 
Localisation image  
 
 
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3. Bladder too large 
No plan selection is acceptable for treatment (without compromise to bladder 
coverage).  
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4. Fiducial marker artefact on CBCT interpretation 
Image below demonstrates effect of lipiodol spill outside bladder resulting in 
significant artefact and degradation of image.  Recommendation is that each CBCT 
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APPENDIX G  
Quick Reference Guide Exporting CBCTs from Aria 
These steps are for guidance only. Please contact your QA group if you have difficulties 
exporting data. 
 
1) Load patient in Aria, go to Offline review and select one (any is ok) of the CBCTs to 
load 
2) Select ‘Session Timeline’ tab at the bottom of the screen 
3) Right click on the CBCT to export and select ‘Export to DICOM’ >> ‘To ‘DICOM Export 
to Pinnacle/External Anonymisation Software/Folder’’ 
4) The Import Export window loads. Select the ‘Show/Hide Tree’ button to bring up a list 
of all CBCTs and registration objects 
5) Select the radio buttons next to the CBCTs to export, using the date to identify them.  




7) Select the radio buttons of the registration objects that have the same date as the 
CBCTs you wish to export.  
 
8) Click the right arrow to export to the export folder/destination. 
 
9) In windows explorer navigate to the export folder/destination and select the CBCTs 
and registration object files. Copy them to the DICOM anonymiser folder and run 
through your anonymiser to anonymise as per standard departmental working 
instructions. Please check the anonymization software does not remove the 
registration objects. If this occurs please contact RTTQA. 
 
10) Save in a folder ready for export to RTTQA. 
 
Please note that, for ease, whole patient exports can be submitted by 
the centre to RTTQA 
For further information on suitable anonymisation software for ARIA 
exports please contact raiderqa.enh-tr@nhs.net  
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APPENDIX H 
Quick Reference Guide Exporting CBCTs from Elekta/XVI 
 
These steps are for guidance only. Please contact your QA group if you have difficulties 
exporting data. 
 
Exporting from XVI  
Images need to be exported individually, not as a treatment.  
1. On the XVI acquisition PC select the image to be exported 
2. Select IMAGE from the tool bar 
2.1. EXPORT 
2.2. DICOM SERVER ‘select TPS/online server’ 
2.3. OK 
3. The next screen gives 3 options 
 Option 1 – In the Option 1 list, select a multiple of the voxel size in the reconstructed 
volume for the CT slice thickness. This can be done without a reference dataset being 
available and hence imports the CBCT into pinnacle without any co-ordinates related 
to the reference image. This is not likely to be useful.  
 
 Option 2 – Only available if image registration was done and approved for this 
reference image. The position of the VolumeView™ exported is the position before 
registration.  
 
 Option 3 – Only available if image registration was done and approved for this 
reference image. The position of the VolumeView™ exported is the position after 
registration.  
 
3.1 Select Option 3 as the information required is as the patient was treated i.e. after 
registration (e.g. if patient was treated with correction). 
NB Registration has to be performed for option 3 to be available.  
3.2. In the Export options area, click the Create CT button. 
3.3 EXPORT 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-041005:e041005. 10 2020;BMJ Open, et al. Hafeez S
RAIDER radiotherapy planning and delivery guidelines 





Exporting CBCTs from Raystation 
 
For centres exporting CBCTs from Raystation please contact raiderqa.enh-tr@nhs.net  
 
This is a controlled document and should not be copied, distributed or reproduced without the 
written permission of the ICR-CTSU 
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A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour 
boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder 
 
PATIENT INFORMATION SHEET 
 
 
We would like to invite you to take part in a research study called RAIDER.  
 
Before you decide whether to take part, it is important that you understand why the 
research is being done and what it would involve for you.  One of your doctors or nurses 
will go through this information sheet with you and answer any questions you may have. 
Please take time to read the information carefully and to discuss it with relatives, friends 
and your GP if you wish. Please ask if anything is unclear or you need any further 
information.  
 
Thank you for reading this and considering taking part in our research. 
 
Why am I being invited to take part? 
We are inviting you to join this study because your doctor has found cancer that has grown 
into the wall of your bladder (muscle invasive bladder cancer) and you are interested in 
receiving radiotherapy treatment which will be given in small doses every day for 7 weeks. 
 
What is radiotherapy treatment? 
Radiotherapy uses targeted beams of high strength x-rays to kill cancer cells.  Because 
radiotherapy can also cause damage to non-cancer cells, the treatment is carefully 
planned by doctors and physicists so that only your bladder and a small border 
surrounding it is treated with the highest radiotherapy dose.  
 
Radiotherapy is individually designed for each patient, based on a CT scan taken a few 
weeks before treatment.  This CT scan tells your doctor about the position and shape of 
your bladder.  
 
The bladder can move within the body depending on how full it is and because of where it 
is in relation to the bowel. It is important that the radiotherapy does not miss any of the 
bladder tumour because of this movement, so a safety margin is added around the bladder 
on the radiotherapy treatment plan. 
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Each patient would usually have one radiotherapy treatment plan designed for them so 
that the radiotherapy is targeted at their tumour.    
 
When radiotherapy treatment is given, the patient lies still on a bed whilst the radiotherapy 
machine moves around to send the radiotherapy beams from different directions.  These 
beams all focus on where the bladder is, to make sure the whole bladder receives the 
highest radiotherapy dose possible. 
 
What is adaptive radiotherapy treatment? 
We are now able to take a scan of where the bladder is when a patient is lying on the 
radiotherapy bed before each treatment. This means we can target the bladder more 
precisely.  
 
In this study we are looking at whether it is possible to design three treatment plans (small, 
medium and large) and then choose the one that best fits the size of the bladder on the 
patient’s treatment day.  This is called ‘adaptive radiotherapy’.  Adaptive radiotherapy may 
allow treatment to be given with smaller safety margins, which may lead to fewer side 
effects.  
 
What is tumour focused radiotherapy treatment? 
It is also possible to focus the highest dose of radiotherapy on the bladder tumour.  This 
means that the rest of the bladder can be given a lower dose of radiotherapy.  This may 
mean fewer side effects as the rest of the bladder will be given less radiotherapy.  It also 
allows us to find out whether a higher dose of radiotherapy can be given only to the tumour 
(tumour boost), to see if this will reduce the chance of the cancer returning, whilst also 
keeping any side effects as mild as possible. 
 
What is the purpose of RAIDER? 
RAIDER is based on a study of adaptive tumour boost radiotherapy which was conducted 
at one UK hospital.  We hope to show that this complex radiotherapy can be given by 
radiotherapy departments at different hospitals. If this is possible, we want to look at 
whether the side effects are similar to those experienced by people receiving standard 
radiotherapy.   
 
RAIDER is based on several smaller studies conducted at hospitals worldwide, which 
suggest that treatment using these radiotherapy techniques could help to reduce side 
effects.  Although these smaller studies are promising, RAIDER is the largest study of 
these techniques and has been designed to give us as much information as possible. We 
will use the results of RAIDER to develop a future study to investigate whether these 
techniques could improve how well radiotherapy cures bladder cancer. 
 
What would happen if I took part? 
At least 240 people in the UK, Australia and New Zealand will be included in RAIDER.  All 
RAIDER participants will be treated with daily radiotherapy. 
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Everyone who agrees to take part in this research study will be in one of three groups: 
 
1. Group 1: Standard radiotherapy: One out of four people taking part will be given 
standard bladder radiotherapy using the same radiotherapy treatment plan each 
time, treating their whole bladder to the same dose of radiotherapy.    
 
2. Group 2: Adaptive tumour focused radiotherapy: One out of four participants will be 
given adaptive tumour focused radiotherapy, using the radiotherapy treatment plan 
which fits the size of their bladder the best.  The standard dose of radiotherapy will 
be targeted at the tumour, with the rest of the bladder receiving a lower dose than 
normal. 
 
3. Group 3: Adaptive tumour boost radiotherapy: Two out of four participants will have 
adaptive tumour boost radiotherapy, using the radiotherapy treatment plan which 
fits the size of their bladder the best. A higher than standard dose of radiotherapy 
will be targeted at the tumour, with the rest of the bladder receiving a lower dose 
than normal. 
 
The only way to make sure that the people in the three groups are as similar as possible is 
to have the treatment decided upon by chance: a process called randomisation.  This 
process ensures that the treatments are compared fully and fairly.  
 
If you agree to take part, your doctor or nurse will ring the research centre.  The centre will 
then record your details and tell your specialist your treatment, which will be selected by 
chance.  This means you could have any of the three treatments described above. 
Whichever group you are in, you will be treated with the best possible care and will be 
monitored closely.   
 
What do I have to do before my radiotherapy treatment? 
To make sure your treatment is as effective as possible, it has to be carefully planned by 
your doctor and other specialised staff (radiographers and physicists). 
 
To help with this, your doctor may wish you to have small markers (fiducial markers) 
placed in your bladder. If this applies to you, you will be given the bladder tumour marker 
information leaflet to read.  
 
You will need to visit the hospital for a planning CT scan before you start radiotherapy.  
The radiographers will also take measurements that are needed for the treatment plan and 
will make small permanent marks which help to line up the radiation beam. Radiotherapy 
is a very precise treatment and it is important that you are able to lie in exactly the same 
position for every treatment. 
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Group 1 – standard radiotherapy planning visit: 
You will have a planning CT scan taken with your bladder empty. All of the planning 
procedures for the standard group are part of the routine care for patients receiving 
bladder radiotherapy, so you would have them even if you choose not to take part in the 
RAIDER research study. The planning session at the radiotherapy department usually 
takes place once and lasts about 30 minutes.   
 
Group 2 and 3 – adaptive tumour focused radiotherapy planning visit: 
If you are in group 2 or 3, we will ask you to empty your bladder and then to drink 350ml of 
water (just over ½ pint).  We will take the first scan at  30 minutes and the next at 60 
minutes after drinking, as your bladder fills. If you decide to join the study you will be given 
a leaflet describing drinking guidelines. The planning session lasts about 70 minutes in 
total, but each scan will only take a few minutes. 
 
What do I have to do during my radiotherapy treatment? 
Your treatment will be given daily.  If you are in group one we will ask you to empty your 
bladder immediately before each treatment. If you are in group 2 or 3, we will ask you to 
empty your bladder and then drink 350mls of water 30 minutes before your planned 
radiotherapy treatment.  
 
For all groups, once the radiographer has helped you to get into position and made sure 
that you are comfortable, we may take a scan in the treatment room. This will take about 2 
minutes. 
 
For patients in group one receiving standard radiotherapy, this scan will be used to make 
sure the bladder is in the area which will receive the highest dose of radiotherapy.  
 
If you are receiving adaptive tumour focused radiotherapy we will use the information from 
the pre-treatment scan to choose the best radiotherapy treatment plan to fit your bladder 
size and the position of your tumour. This will take around five to ten minutes. The plan will 
be selected by a specially trained doctor or radiographer and checked by a second trained 
person before you receive your radiotherapy treatment.  
 
You will need to lie still for up to 20 minutes whilst the machine moves around you to 
deliver the radiotherapy from different angles. You will not feel anything, as it is similar to 
having an x-ray.  
 
During your radiotherapy treatment you will be seen by your doctor and/or 
nurse/radiographer every week to record and treat any side effects that you may be 
experiencing.  They will also take a small sample of blood before treatment starts and 
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Chemotherapy treatment during radiotherapy 
Your doctor may suggest that you also have chemotherapy while you have your 
radiotherapy treatment.  You will be able to take part in RAIDER whether or not you have 
chemotherapy.  Your doctor will discuss the possibility of chemotherapy with you. 
 
How often will I need to visit the hospital after my treatment? 
Everyone in the RAIDER study will be asked to visit the hospital for check-ups on the 
same schedule after treatment,as described below: 
• 10 weeks after the start of radiotherapy: assessment of side effects  
• 3 months after the end of radiotherapy: cystoscopy (inspection of your bladder with a 
telescope) under general anaesthetic & biopsy of the site of the tumour; blood 
sample; chest x-ray; assessment of side effects 
• 6 months: cystoscopy under local anaesthetic; blood sample; CT scan of abdomen 
and pelvis; chest x-ray or CT scan; assessment of side effects  
• 9 months: cystoscopy under local anaesthetic; assessment of side effects 
• 12 months: cystoscopy under local anaesthetic; CT scan of abdomen and pelvis; 
chest x-ray or CT scan; assessment of side effects 
• 18 months: cystoscopy under local anaesthetic; chest x-ray or CT scan; assessment 
of side effects  
• 24 months: cystoscopy under local anaesthetic; CT scan of abdomen and pelvis; 
chest x-ray or CT scan; assessment of side effects 
• 36, 48, 60 months: cystoscopy under local anaesthetic; chest x-ray; assessment of 
side effects 
 
A summary of these visits is on page 15 of the patient information sheet, for your reference 
should you decide to join the study. 
 
 
These visits have been designed to be as similar as possible to what would happen if you 
decided not to join the RAIDER study. If your cancer is found to have returned during 
study check-ups your doctor will discuss further treatment options with you. 
 
After your 5 year (60 month) visit, we would like to collect basic information about your 
health from any routine follow up visits you have, and also from national electronic 
databases which are kept on everyone’s health status. 
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Not all patients will experience all of these side effects and we can give you 
medications to treat any side effects you may experience. 
 
You will be able to carry out most of your normal activities during radiotherapy, but you 
may feel more tired than normal and may need to rest more. 
 
Side effects that can develop during radiotherapy may include: 
• diarrhoea (around 3 in 10 people) 
• needing to urinate more often (around 5 in 10 people) 
• bleeding, pain or discomfort on passing urine (around 2 in 10 people) 
• passing stools more frequently or with pain (around 1 in 10 people) 
 
Some side effects can develop several months after radiotherapy ends.  These include: 
• a need to urinate more often or more urgently (around 2 in 10 people) 
• bowel changes due to scarring or bleeding (around 5 in 100 people) 
• vaginal scarring (around 3 in 10 women) 
• problems with getting and maintaining erections (around 2 in 10 men) 
• infertility (all women, around 5 in 10 men) 
 
A few patients may develop long term effects. These are usually mild but may occasionally 
be serious and require treatment.  
 
If you are in group 3 and receive a tumour focused boost as part of your radiotherapy 
treatment, you will be receiving a higher total dose of radiotherapy to the tumour than 
people in other groups. There is therefore a possible increased risk of radiotherapy side 
effects, but the radiotherapy techniques used in this trial aim to keep the risk of side effects 
similar to those experienced following the standard dose.  Side effects in group 3 will be 
very closely monitored throughout the study and if they appear to be higher than expected, 
treatment within this group will be stopped, and everyone in group 3 will receive standard 
dose tumour focused radiotherapy. 
 
Do I have to take part? 
No, it is up to you to decide whether to take part or not. If you decide to take part, you will 
be given this information sheet to keep and will be asked to sign a consent form. You are 
free to change your mind and withdraw from the study at any time without giving a reason. 
If you do choose to withdraw, your doctor will discuss with you the best treatment options 
available. 
 
What are the alternatives to this study? 
If you decide not to participate in this study, it will not affect the usual standard of care you 
receive. Standard recommended treatments for muscle invasive bladder cancer are 
surgery to remove the bladder or daily radiotherapy using one treatment plan and the 
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same dose to treat the whole bladder.  If you do not take part in RAIDER your doctor will 
discuss all your alternative options with you. 
 
What are the possible benefits of taking part? 
Everyone in the study will receive scans regularly throughout treatment. This may make 
the radiotherapy more accurate than if it was given without the scan. If you are in the 
adaptive radiotherapy groups you will receive radiotherapy treatment with the smallest 
possible safety margin each time and this may reduce the risk of side effects.  If you are in 
the tumour focused boost group, the increased radiation dose to your tumour may control 
your bladder cancer better. 
 
What are the possible disadvantages of taking part? 
Tumour focused adaptive radiotherapy could cause an increased risk of missing the 
tumour, but everyone who gives treatment as part of RAIDER will be fully trained and 
treatment will be checked by a second trained observer before it is given.  There is also a 
risk that sparing the bladder from exposure to full dose radiotherapy could cause an 
increased risk of the cancer returning elsewhere in the bladder, however previous studies 
have not suggested this, and any indication of this will be carefully monitored in all patients 
who join RAIDER. 
 
It is possible that the side effects of tumour focused boost radiotherapy might be worse 
than with standard treatment, but this will be monitored for all RAIDER participants and the 
study will be stopped if people experience bad side effects.  
 
The selection and confirmation of the radiotherapy treatment plan will extend the length of 
each radiotherapy treatment by about 5 to 10 minutes for patients receiving adaptive 
radiotherapy. 
 
You may have more CT scans than you would if you did not take part in RAIDER because 
you will have one before each treatment, and if you are in the tumour focused groups you 
will have two planning scans rather than one.  If you are in the tumour focused boost group 
you will receive a higher dose of radiotherapy than you would otherwise.  All of these 
factors mean that you could be exposed to more radiation than you would be otherwise, 
which may lead to an increased risk of developing a second cancer later in life. 
 
Before participating you should also consider if this will affect any insurance you have and 
seek advice if necessary. 
 
How will confidentiality be maintained? 
Your medical notes will be seen by authorised members of the research team at your 
hospital, so that they can collect information needed for the RAIDER study.  When you join 
the study, your name, date of birth, postcode, hospital number and NHS or Community 
Health Index (CHI) number will be passed to the Institute of Cancer Research Clinical 
Trials and Statistics Unit(ICR-CTSU) where the study is being coordinated. You will be 
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given a unique registration number, which will be used together with your initials and date 
of birth on forms that the research staff will send to the ICR-CTSU. All information about 
you will be coded with this registration number and will be stored securely. It will be treated 
as strictly confidential and nothing that might identify you will be revealed to any third 
party. 
 
Scientific employees of ICR-CTSU, and those conducting the study with them, including 
the national radiotherapy quality assurance team, may need to examine your medical 
records to ensure the study is being run properly and that the information collected on the 
forms is correct, but your confidentiality will be protected at all times.   
 
We will contact your hospital over the years to find out how you are getting on. Ideally we 
would like to do this for life, but patients often change address or GP or lose touch with 
their hospital. If this happens we would like to use national records which are kept on 
everyone’s health status to find out how you are. One of these is held at the General 
Register Office (GRO). We will need to give them enough information to identify you. This 
is usually your name, date of birth and NHS number (or Community Health Index and/or 
hospital number in Scotland). These details are confidential and will only be used for the 
purposes of the RAIDER study. Please initial the consent form to show that we have your 
permission to do this – if you do not agree, we will not seek this information. 
 
The Institute of Cancer Research is the Sponsor for this study based in the United 
Kingdom. We will be using information from you and/or your medical records in order to 
undertake this study and will act as the data controller for this study. This means that we 
are responsible for looking after your information and using it properly. Our legal basis for 
processing your data is task in the public interest for scientific research purposes. The 
Institute of Cancer Research will keep identifiable information about you for 20 years after 
the study has finished.  
 
Your rights to access, change or move your information are limited, as we need to manage 
your information in specific ways in order for the research to be reliable and accurate. If 
you withdraw from the study, we will keep the information about you that we have already 
obtained. To safeguard your rights, we will use the minimum personally-identifiable 
information possible.  
 




[NHS site] will collect information from you and/or your medical records for this research 
study in accordance with our instructions. 
 
[NHS site] will use your name, NHS number and contact details to contact you about the 
research study, and make sure that relevant information about the study is recorded for 
your care, and to oversee the quality of the study. Individuals from The Institute of Cancer 
Research and regulatory organisations may look at your medical and research records to 
check the accuracy of the research study. [NHS site] will pass these details to The Institute 
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of Cancer Research along with the information collected from you and/or your medical 
records. The only people in The Institute of Cancer Research who will have access to 
information that identifies you will be people who need to contact you to send a Quality of 
Life booklet by post or audit the data collection process. Only members of the research 
teams at your hospital and the ICR-CTSU will have access to the information that could 
allow this trial ID number to be linked to you. 
 
[NHS site] will keep identifiable information about you from this study for 20 years after the 




When you agree to take part in a research study, the information about your health and 
care may be provided to researchers running other research studies in this organisation 
and in other organisations. These organisations may be universities, NHS organisations or 
companies involved in health and care research in this country or abroad. Your information 
will only be used by organisations and researchers to conduct research in accordance with 
the UK Policy Framework for Health and Social Care Research.  
 
Your information could be used for research in any aspect of health or care, and could be 
combined with information about you from other sources held by researchers, the NHS or 
government.  
 
Where this information could identify you, the information will be held securely with strict 
arrangements about who can access the information. The information will only be used for 
the purpose of health and care research, or to contact you about future opportunities to 
participate in research. It will not be used to make decisions about future services 
available to you, such as insurance.  
 
Where there is a risk that you can be identified your data will only be used in research that 
has been independently reviewed by an ethics committee.  
 
 
What will happen to the results of the research study? 
Independent experts will review the safety and progress of the research whilst it is being 
carried out, and the results will be published in a respected medical journal once we are 
sure they are reliable. No information that could identify you will be included and you will 
not be identified in any report or publication.  
 
We will summarise the results for participants once they are available. Your hospital will be 
able to give you a copy and results will also be available on Cancer Research UK’s patient 
website (www.cancerhelp.org.uk). 
 
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, 
your doctor will tell you and discuss whether you should continue in the study. If you 
decide not to carry on, your doctor will make arrangements for your care to continue. 
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Will I be paid for taking part in this study? 
No. Neither you nor your doctor will be paid for taking part in this study. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during this study, or any possible 
harm you might suffer, will be addressed.  Your progress will be watched closely and you 
will be offered whatever help is available to cope with any side effects. Occasionally some 
patients need a short stay in hospital for side effects to be treated, and on rare occasions 
these can be serious. If this were to happen, full details of what has happened will be 
reviewed carefully by the Doctor who has overall responsibility for the RAIDER study . It is 
unlikely that anything will go wrong with your treatment or care, but if you wish to complain 
about any aspect of the way you have been approached or treated during the course of 
the study you can do so using the normal NHS complaints procedure. Concerns should be 
raised by speaking to a member of staff at your hospital or by talking to the local Patient 
Advice and Liaison Service (PALS) which has been established in every NHS Trust.  
 
NHS bodies are liable for clinical negligence and other negligent harm to individuals 
covered by their duty of care. In the event that something does go wrong and you are 
harmed during the research and this is due to someone‘s negligence then you may have 
grounds for a legal action for compensation against the NHS Trust but you may have to 
pay your legal costs. Alternative indemnity arrangements apply to private clinics. 
 
What if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time.  You do not have to give a reason and 
your future treatment and care will not be affected.  If you change your mind about having 
treatment or follow up within this study, we would still like to collect information about how 
you are getting on. The information we need is routinely recorded in your medical records 
at your standard hospital visits and you would not need to do anything.  
 
Who is organising and funding the research?  
RAIDER is organised by doctors at the Royal Marsden Hospital in London, in collaboration 
with other leading doctors across the country and the Institute of Cancer Research Clinical 
Trials and Statistics Unit in London. The research is approved and funded by Cancer 
Research UK, who are providing funding to run the trial in the UK.  The National Health 
Service Research and Development Executive will pay for any extra nursing and 
administrative costs incurred by participating hospitals and the National Institute for Health 
Research will pay for some of the costs of conducting the research at participating 
hospitals.   
 
Who reviewed this study? 
All research in the NHS is reviewed by an independent group of people, called a Research 
Ethics Committee, to protect participants’ safety, rights, wellbeing and dignity.  RAIDER 
has been reviewed and approved by London – Surrey Borders Ethics Committee on behalf 
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of all hospitals throughout the UK. It has also been reviewed and approved by Cancer 
Research UK and reviewed and endorsed by patient and carer representatives from the 
NCRI Consumer Liaison Group (www.ncri.org.uk).  
 
What happens now? 
You will have some time to think about the study and make your decision. Your doctor, 
nurse or radiographer will be happy to answer any questions. You may wish to discuss it 
with your family or friends. Once you have reached your decision please let your doctor or 
nurse know.  You will be asked to sign a consent form and will be given a copy to keep 
together with this information sheet. Please keep this information sheet and copies of the 
signed consent form. Your GP will be told that you are taking part in the RAIDER study.  If 




Macmillan Cancer support  is a registered charity and  helps with all the things that people 
affected by cancer want and need, from specialist health care and information to practical, 
emotional and financial support (www.macmillan.org.uk).You can also learn more about 
clinical trials on the Cancer Research UK’s patient website (www.cancerhelp.org.uk). 
 
Contact details 
If at any time you have any questions about the study please contact your local study 
team: 
Local consultant’s name: 
Local research nurse/radiographer: 
Address: 
Telephone: 
24 hour contact number: 
 
Thank you for your interest in our research. 
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Optional components to the study: 
 
If you agree to participate in the main RAIDER trial, you will be invited to take part in the 
following sub-studies: 
 
1. Side effects questionnaire study 
2. Donation of routine samples from surgery 
 
If I want to be part of the RAIDER study, do I have to take part in the sub-studies? 
 
No. Taking part in RAIDER does not mean you have to take part in the sub-studies. You 
will be given the chance to discuss RAIDER and you can then decide whether you want to 
take part.  
 
The following pages of this information sheet give further details about these sub-studies. 
 
 
1. Side effects questionnaire study 
The main reason we are carrying out the RAIDER study is to look at the side effects of the 
radiotherapy treatment. If you decide to take part in RAIDER, we would like you to 
complete short questionnaires to describe any side effects that you may experience.  
 
This is an optional part of the study but completed questionnaires will help us to 
understand more about the side effects of this radiotherapy treatment from your point of 
view.  Completing a questionnaire should take no longer than 20 minutes. 
 
If you agree to take part, we will ask you to fill in a questionnaire before you start 
radiotherapy, at the end of your radiotherapy treatment and then at 3, 6, 12, 18 and 24 
months afterwards. We know from other patients that they feel such surveys are very 
important, but you do not have to complete them if you do not want to. 
 
The first questionnaires will be given to you by your hospital.  From 6 months onwards 
questionnaires will be posted to you at your home address by The Institute of Cancer 
Research Clinical Trials & Statistics Unit (ICR-CTSU).  
 
Before sending you the questionnaire, ICR-CTSU will contact your hospital or GP to check 
how you are; therefore we would like to ask for your permission to give ICR-CTSU your full 
name and address as well as your GP’s name and address.  If you agree to this, please 
initial the consent form to show that we have your permission. 
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2. Donating samples from surgery 
RAIDER gives us the opportunity to ask many people with cancer similar to yours whether 
we can collect samples that will aid future research. 
 
When you were diagnosed bladder cancer, your hospital will have kept a sample of the 
tumour your surgeon removed during surgery.  We would like your permission to collect 
this and samples which are taken at any future surgery you may have, so that we can look 
at it in combination with samples from other people who have joined the study.  This will 
allow us to test for genetic differences in the make-up of individuals, indicate why they 
develop cancer and predict how they react to treatment.  If we show that genetic 
differences do explain why some patients develop bladder cancer or react to their 
treatment differently, this knowledge could help many patients in the future.   Any genetic 
analysis would be for research purposes only and will not affect any insurance you may 
hold. 
 
When they are collected from your hospital, the samples will be coded and your personal 
details will be removed.  The coding will maintain your confidentiality whilst allowing 
biological details to be compared to treatment findings. 
 
The samples collected in this study will be stored indefinitely.  It is possible that in the 
future other research may be carried out on the samples collected within this trial.  This 
research may be conducted in the UK or overseas. Your personal details will not be 
shared with other researchers.  Any future research on samples will be approved by an 
ethics committee before it is done. 
 
Sample donation is entirely optional and you do not have to participate if you do not wish 
to.  If you chose to join the study there will be a section to complete when you sign the 
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Summary of study assessments  
 






















              



























































































Assessment of side 
effects 
          
Blood sample           
Cystoscopy under 
general anæsthetic 




         
Cytoscopy under local 
anæsthetic 
          
Chest x-ray           
CT scan of abdomen 
& pelvis 
          
Chest x-ray or CT 
scan 
          
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(Form to be printed on hospital’s headed paper)  
CONSENT FORM  
 
RAIDER: 
A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour 
boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder 
 
Ethics Committee Reference: 15/LO/0539 
 
RAIDER trial ID: 
 
Name of Researcher taking consent:  
 
Please write your initials in the box to the right of each statement if you agree, and 
please sign at the bottom  
 
  Initials 
1. I confirm that I have read and understand the RAIDER Patient 
Information Sheet 32f Version 2.0 dated 23/01/2019 for the 
above study. I have had the opportunity to consider the 
information, ask questions and have had these answered 
satisfactorily.  
 
   
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my 
medical care or legal rights being affected.  
 
   
3. If I withdraw from the study, I consent to my doctor providing 
authorised researchers with basic clinical information that would 
be routinely collected and written in my medical records. 
 
   
4. I understand that sections of any of my medical notes may be 
looked at by responsible individuals from the research team, from 
ethics committees, or from the NHS Trust, where it is relevant to 
my taking part in research. I give permission for these individuals 
to have access to my records. 
 
   
5. I consent to the Institute of Cancer Research using information 
held by the NHS and national databases to follow up my health 
status. 
 
   
6. 
I agree to my GP being informed of my participation in the study.   
   
7. 
Data sharing: I grant advance authorisation for the possible future 
sharing of information collected about me with other 
organisations, with the understanding that I will not be identifiable 
from this information (optional). 
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8. I agree to participate in the side effects questionnaire study. 
(optional) 
 
   
8a. I consent to researchers from The Institute of Cancer 
Research being sent my address and GP contact details. 
 
   
8b. I consent to researchers from The Institute of Cancer 
Research contacting my GP to confirm I am fit and well to 
receive questionnaire booklets to be sent out by post. 
 
   
8c. I consent to my GP disclosing my health status to 
researchers from The Institute of Cancer Research 
 
   
9. I consent to donating routinely collected samples from surgery 
(optional) 
 
   
9a. I agree that my tumour tissue samples will be analysed for 
potential changes in DNA (genetic changes) 
 
   
9b. I grant advance authorisation for the possible future sharing 
of information collected about me with other organisations, 
with the understanding that I will not be identifiable from this 
information 
 
   
9c. I grant advance authorisation for possible future research on 
my stored samples, with the understanding that I will not be 
identifiable from these samples.  I understand that that 
approval of an ethics committee will be obtained beforehand. 
 
   
















Name of person taking consent Date Signature 
 
1 copy for participant; 1 copy for Principal Investigator; 1 copy to be kept with hospital notes 
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